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ABSTRACT
INTRODUCTION: Early identification and early childhood intervention are known to improve
cognitive, social, and adaptive functioning and improve the quality of life of children diagnosed
with autism spectrum disorders. Since early intervention and treatment success depends on early
identification, early childhood screening with high-quality screening tools is critical. Recovering
missing data and adjusting the data for epidemiologically reported prevalence can provide more
accurate estimates of missed cases when studies report results without follow-up data to verify
missed cases.

AIM: The purpose of this study was to conduct an umbrella review and meta-analysis of
diagnostic accuracy (MADA) of autism spectrum disorder (ASD) screening tools to evaluate the
effect of three missing data and prevalence adjustment methods on pooled diagnostic accuracy
metrics.

METHODS: This study selected a final sample size of 28 previously reviewed population-level
studies for inclusion that focused on children ages 6 to 72 months (total screened = 205,934).
The three data adjustments included: recovering missing or unreported data using standard
diagnostic accuracy formulas; epidemiologically adjusting the recovered data using reported
ASD prevalence by year and nation of origin; epidemiologically adjusting the recovered data
using CDC yearly reported ASD prevalence. Using a bivariate random effects Reitsma model,
the study calculated pooled sensitivity, specificity, and a pooled diagnostic odds ratio for each
data adjustment approach. The bivariate analysis also applied metaregression models to
simultaneously compare the pooled sensitivity and false positive rate for each data adjustment.

vi

RESULTS: Sensitivity systematically decreased for each data source in both the univariate and
bivariate analyses. Recovering missing data increased sensitivity in the univariate and bivariate
analysis (Se = 0.732 and Se = 0.759, respectively). Univariate sensitivity decreased after the
national (Se = 0.628) and CDC prevalence (.422) adjustments. Sensitivity in the bivariate
analysis decreased after the national (Se = .652) and CDC prevalence (Se = .384) adjustments.
The current results suggest that recovering missing data and adjusting for national prevalence
may be an appropriate data adjustment method to obtain unbiased assessments of diagnostic
accuracy and help detect screening tools weaker than those promoted from cross-sectional
studies.
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INTRODUCTION

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder wherein individuals
present with persistent deficits in social cognition across multiple contexts, including social
interactions and interpersonal communication, deficits in social-emotional reciprocity, deficits in
nonverbal communicative behaviors used for social interaction, and in developing, maintaining
and understanding relationships (DSM-V, 2013). Different levels of autism vary regarding the
degree of social communication deficits and the degree to which someone with ASD exhibits
preferred attention for repetitive behaviors and fixations on a limited set of preferred activities
and stereotyped behaviors (DSM-5, 2013). ASD is highly heritable, and conservative estimates
suggest that 10–20% of diagnosed autism cases carry rare point de novo point mutations in their
genetic code (Iossifov et al., 2014).
While there is no known prevention for ASD, research shows that early screening leading
to intervention can result in reduced deficits in social cognition and communication (Estes et al.,
2015; Gabbay-Dizdar et al., 2021; Maenner et al., 2021). Autism can be indicated by
neuropsychological screening as early as ages 12 to 24 months (Wetherby et al., 2008). In recent
years, autism is usually identified via a formal clinical diagnosis before a child enters the K12
school system (CDC, 2021). According to the Centers for Disease Control (CDC, 2021), 1 in 44
(2.3%) children from 11 communities in the US were diagnosed with autism as of 2018.
The path to identification, diagnosis, and treatment is exceedingly difficult for many
parents and caregivers (Eaves et al., 2006; McCarty and Frye, 2020). Although it is possible to
detect many cases of autism by 24 months of age (Kleinman et al., 2008; Wetherby et al., 2008),
most cases are diagnosed later between the ages of 48-60 months (Baio et al., 2018, Mandell et
al., 2006). The process of obtaining a diagnosis is often delayed due to the complexity of the
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early identification process, which requires multiple clinical assessments before a child can
receive a diagnosis (Goin-Kochel et al., 2006). Children who are often successfully diagnosed at
early ages come from families where the parents attained higher education levels, suggesting a
socio-economic disparity in early identification and intervention in autism (Goin-Kochel et al.,
2006). Numerous children are delayed in receiving a diagnosis, and many children with a
detectable presentation of ASD may not receive a diagnosis due to the diagnosis process's
complexity. Without an early diagnosis, these children will miss out on the benefits of early
intervention.
Past and recent research suggests that early identification of autism is critical to ensuring
positive outcomes for individuals with the condition. If children are identified early, a
subsequent intensive early behavioral intervention for autism will have a greater chance of longlasting generalizable improvements in cognitive, social, and adaptive functioning (Estes et al.,
2015; Gabbay-Dizdar et al., 2021; McCarty & Frye, 2020). Since early intervention and
treatment success depends on early identification, early childhood screening is critical.
1.1

The Process Model and Early Identification
The process model generally follows four main stages (Barger, Rice, and Simmons,

2018). The first stage begins with community concern monitoring, often first with caregivers.
Screening and monitoring are the process model's first stages yet separate processes. Monitoring
is the ongoing surveillance of pediatric healthcare status reported by pediatric healthcare
providers (Barger et al., 2022; Maenner et al., 2021). The second stage is early detection
screening and often overlaps with monitoring. Monitoring or screening resulting in concerns
leads to a referral for the third stage, a diagnostic assessment in a clinical or educational setting.
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The fourth and final stage is diagnostic verification and receipt of services to meet the need for
early intervention.
Screening is typically conducted using a standardized tool, such as the Modified
Checklist for Autism in Toddlers (M-CHAT) (Chlebowski et al., 2013; Kleinman et al., 2008;
Robins et al., 2014). Upon a screening tool flagging a concern, a referral is made to a specialist
for a comprehensive diagnostic evaluation using assessment tools (e.g., the Autism Diagnostic
Observation Schedule, ADOS). An evaluation typically includes a clinical interview, a review of
the individual's developmental history, and a comprehensive assessment of the individual's
cognitive, social, and adaptive functioning (Estes et al., 2015; Rogers & Vismara, 2008).
Since the early 2000s, several autism screening tools have been developed that show
promise for generalizability across cultures and populations. For example, Zarohodny et al.
evaluated the Psychological Development Questionnaire-1 PDQ-1 using a large and diverse
sample to screen children 31 to 36 months (Zahorodny et al., 2018). The psychometric properties
of the PDQ-1 were high quality, with sensitivity between .71 -1.0, specificity between .99-1.0, a
positive predictive value of .79 -1.0, and a negative predictive value of .99-10. Sturner et al.
(2016) compared the diagnostic accuracy of the M-CHAT to the Q-CHAT-10. They found that
the M-CHAT performed better in specificity and positive predictive value upon follow-up, while
the Q-CHAT-10 had a higher sensitivity and did not require follow-up. Furthermore, the authors
found that the Q-CHAT-10 did not differ in screening performance by income and the tool’s use
of graded responses and further suggest that using images in place of words in some contexts
may decrease cultural bias (Sturner et al., 2016).
According to the American Academy of Pediatrics, monitoring is defined as the ongoing
observation, consideration, and recording of developmental concerns as noted in a child’s health
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records, regardless of whether they were identified with a screening tool (Lipkin and Macias
2020). The Centers for Disease Control (CDC) and other organizations have created monitoring
tools like ‘Learn the Signs. Act Early (CDC, 2021), which highlighted the importance of
informal parental monitoring (Raspa et al., 2015). Monitoring of children allows care providers
and caretakers to determine if children are on track for their development. The research also
suggests that ASD cases among minority children who are missed with screening may be
identified through careful monitoring of development (Barger et al., 2022; Guthrie et al., 2019).
Relative to monitoring, autism screening and clinical assessment are much more
commonly studied (Yuen et al., 2018; Oner et al., 2019; Hoang et al., 2019; Tsai et al., 2019;
Fäldt et al., 2021). Early autism identification is a community-based process wherein early health
and/or education providers refer caregivers to early intervention or community-based
assessments to determine if there is a clinical concern requiring treatment (Barger, Rice, and
Simmons, 2018). Historically, screening and assessment studies have primarily been conducted
by clinical psychologists to establish the psychometric reliability, validity, and accuracy of
available tools. However, autism spectrum disorder screening is a process by which children in
the general population are first identified as at risk for ASD; the primary benefit of early
screening is identifying children with developmental delays who need additional support from
preschool age (Gabbay-Dizdar et al., 2021; Barger, Rice and Roach, 2021).
Notably, early identification processes typically occur in relation to two systems: medical
and educational. The federal government-sponsored Individuals with Disabilities Education
Improvement Act provides funding for early childhood special education programs serving
children ages three to five. Further, a medical screening culminates in a formal diagnosis that
meets the requirements of the DSM-V characteristics and icd-10 description. Educational
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institutions require evidence of negative educational impacts before a child can receive ASD
classification, and their criteria do not always follow the DSM-V criteria (Thabtah & Peebles,
2019). The ultimate clinical goal of these early identification efforts is to ensure the timely
receipt of interventions. At the same time, children are young enough to optimally benefit from
early childhood autism interventions that aim to curb and moderate developmental delays in
communication and social skills, which are paramount for early success in school.
Timely early intervention can result in more positive results than interventions received
later (McCarty & Frye, 2020, 2020; Pierce et al., 2011). For example, recent studies showed that
children who received early intervention for autism had better social skills, communication
skills, and adaptive behavior than those who did not receive early intervention (Gabbay-Dizdar et
al., 2021; Kim et al., 2018). Additional evidence highlights the impact of early intervention for
ASD on achieving better outcomes in IQ and cognitive functioning, adaptive behavior, and
social functioning (Estes et al., 2015; Rogers & Vismara, 2008). The efficacy of treatment
depends on the early identification of ASD. If autism is detected early in a child's development,
by or before 30 months of age, early intervention in the form of behavioral therapy can help a
child keep or retain speech and develop better social cognition. Over 65% of children identified
before 2.5 years of age improved their social communication skills (Gabbay-Dizdar et al., 2021).
In short, earlier interventions targeting children 24-30 months of age increase the odds of
positive developmental outcomes. Ultimately, children identified early through developmental
screening and monitoring are much more likely to receive early childhood special education
services (Barger, Rice, and Roach, 2021). Thus, early screening and assessment are critical to
ensure that children with ASD receive early interventions and treatment. (Barger et al., 2021;
Gabbay-Dizdar et al., 2021).
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What is the relationship between screening and a “gold standard” diagnosis?
Establishing best practices for assessment and detection is critical when considering early

identification. While some conditions have very clear genetic binary markers, ASD is a
behavioral spectrum requiring intensive clinical training for professionals to learn how to
distinguish the behaviors of children with ASD from other neurological conditions with different
but similar presentations. Therefore, no specific measure is considered the “gold standard” for
autism detection and identification. Instead, the ‘gold standard’ for detecting and diagnosing
ASD is the approach that uses a multi-informant multidisciplinary diagnosis informed by high
quality recommended diagnostic assessments (Klin & Volkmar, 1995; Klin et al., 2005). A gold
standard measurement approach incorporates the best field vetted tools and resources to acquire
the most accurate assessment for diagnosis.
One extensively researched and documented high quality assessment tool often referred to
inaccurately as “gold standard” is the Autism Diagnostic Interview-Revised (Lord, Rutter & Le
Couteur, 1994). The Autism Diagnostic Interview-Revised (ADI-R) uses a semi-structured
interview that can be administered by a trained clinician or researcher (Lord, Rutter & Le
Couteur, 1994). The ADI-R includes an exhaustive list of items specific to autism related to
onset patterns and timing of behavior, communication, social development, play style, and
restricted interests and behaviors (Lord, Rutter & Le Couteur, 1994). The ADI-R has good testretest reliability and convergent and discriminant validity with other ASD measures (Lord,
Rutter & Le Couteur, 1994). In a recent study, the ADI-R was found to have excellent diagnostic
accuracy, with a sensitivity of 93% and a specificity of 100% for the diagnosis of ASD
(Tavassoli et al., 2014).
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The Autism Diagnostic Observation Schedule (ADOS) (Lebersfeld et al., 2021) is a semistructured standard diagnostic tool used for direct parent interviewing that uses a play
environment to collect observational data on children under assessment. The ADOS has good
test-retest reliability and convergent and discriminant validity with other ASD measures (Lord et
al., 2012). In a recent study, the ADOS was found to have excellent diagnostic accuracy, with a
sensitivity ranging from .89 to .92 and a specificity ranging from .81-.85 for identifying ASD
(Lebersfeld et al., 2021). These findings suggest that the ADOS/ADOS-2 is a reliable and valid
tool for diagnosing ASD. High quality diagnostic tools using a multidisciplinary team diagnosis
that show reliability in the field and stand up to robustness checks in systematic reviews and
meta-analyses over time inform and guide the development of a gold standard process for
detecting and diagnosing autism.
The optimal screening tool is one that is sensitive enough to accurately detect children
with ASD and screen out children without ASD, minimize misdiagnosis of children without
ASD, and negatively screen children with ASD. Over time, the field has struggled with ensuring
that screening tools are optimized, and researchers have differentially focused on specific aspects
of identification. For example, to minimize the cost associated with assessing children without
ASD, as in reducing the frequency of missed cases, several teams worked to develop level 2
screeners designed to screen out non-cases that are often falsely identified as cases by the first
screen (McCarty & Frye, 2020). Because of the low prevalence of ASD, the number of children
accurately identified with the most often used tools may remain low, resulting in the screening
missing up to one in three children (McCarty & Frye, 2020).
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Measuring Diagnostic Accuracy
Diagnostic accuracy is determined by how well a screening tool can classify a population

according to whether they have a condition or do not have a condition (Shreffler and Huecker,
2021). Diagnostic accuracy metrics are developed by constructing a confusion matrix, a form of
a 2x2 contingency table (Pearson, 1904), that measures the frequencies of the following:
correctly classified patient cases or true positives (TP); falsely identified cases or false positives
(FP) who do not have the condition; and persons with the disorder who were initially
misclassified as ‘without the condition’ by the screening test, or a false negative (FN); and lastly,
the true negative (TN) that is truly without the condition and was screened negative by a clinical
screening tool. A true positive (TP) is a case that was correctly classified by the clinical
screening test. A false negative (FN) occurs when a case is missed by the screening test in error
(Figure 1).
Figure 1
Confusion Matrix of Measures
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Numerous diagnostic accuracy metrics may be rendered from the elements of a confusion
matrix. Sensitivity (Se) is the proportion of people in the screening population with a condition
who received a positive screening out of all people in the population with the condition (TP/
TP+FN). Specificity (Sp) is the proportion of people in the population without the condition who
received a negative screening out of all actual non-cases (TN/TN+FP). Including information
about sensitivity and specificity is paramount for good clinical reporting. However, Se and Sp
alone may lack precision for measuring the effectiveness of a screening tool for low prevalence
conditions (Akobeng, 2017). Furthermore, positive predictive value (PPV) refers to the
probability that a screening tool will correctly identify all people in the population who have the
condition out of all people in the population who received a positive screening. The negative
predictive value (NPV) refers to the probability that a screening tool will correctly “rule out” all
people in the population who have the condition out of all people who received a negative
screening. Alternatively, the PPV of a diagnostic screening test is the probability of having the
condition given a positive test result, and the NPV is the probability of not having the condition
given a negative result.
In addition to metrics rendered from the raw matrix information, several metrics may be
rendered from sensitivity and specificity. For example, the diagnostic odds ratio (DOR) is often a
single test method of measuring the effectiveness of a diagnostic screening tool. The calculation
of the DOR relies on two additional measures, the positive likelihood ratio (LR+) and the
negative likelihood ratio (LR-). The positive likelihood ratio is the probability of an expected
positive screening divided by the probability of the expected positive screening among those
without the disease or the true positive rate (TPR) divided by the false positivity rate (Shreffler
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and Hueker, 2022). The negative likelihood ratio (LR-) is the probability of an expected
negative test result out of those with the condition divided by the probability of a patient testing
negative without the condition. The formulas for LR+, LR-, and DOR, are included below (Table
1).

Table 1
Diagnostic Accuracy Measures Formulas
Se and Sp
TP

Sensitivity = TP/(TP+FN)

DOR
LR+/LR-

LR+ = Sens/(1 - Sp)

FN

TN

LR

Specificity = TN/ (TN + FP)

LR- = (1-Sens)/Sp

FP

The overall raw accuracy of a screening tool or algorithm can be calculated as the
proportion of all true positives and true negatives out of the total population. However, this
information is not very useful for clinical diagnostic accuracy when the goal of a screening
instrument is to correctly identify cases with the condition or disease that require intervention.
Determining who receives treatment requires more precision than a simple ‘accuracy’ measure,
which measures the overall test performance but does not measure case identification accuracy
directly. The goal of diagnostic testing is to identify autistic traits for children at risk who are
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then referred to a clinician for diagnosis so that the child can qualify for educational benefits and
services and receive a targeted intervention plan (Thabtah and Peebles, 2019).
1.4

Example of ASD Screening Complexity: The Modified Checklist for Autism in
Toddlers
The Modified Checklist for Autism in Toddlers (M-CHAT), and associated versions

(Robins et al., 2001; Baron-Cohen et al., 1996) collectively, is one example of an extensively
researched high quality ASD screening tool. The M-CHAT is a 23-item ‘yes/no’ screening tool
developed at Georgia State University by Diana Robins, Ph.D., as a follow-up to the original
tool, the Checklist for Autism in Toddlers (CHAT) (Robins et al., 2001). The M-CHAT is
administered as a parental questionnaire in paper or electronic form and was designed to
maximize sensitivity to identify children ages 16-30 months who are deemed ‘at-risk’ for autism
(Robins et al., 2001; Baduel et al., 2017). However, maximizing the sensitivity of the M-CHAT
often resulted in high false positives (Kleinman et al., 2008; Robins et al., 2014). The M-CHAT
was revised to include follow-up and renamed the MCHAT Revised with Follow-up (M-CHAT
R/F) (Robins et al., 2014). The revised form of the M-CHAT includes a structured follow-up
interview (FUI) for the parents of children who were screened as positive following a two-step
process that was implemented to reduce the frequency of false positive results (Robins et al.,
2014). Some of the original screening items based on play behavior were dropped, reducing the
total number of items to 20. (Appendix A).
Past reviews of the M-CHAT noted that higher PPV depended on the FUI and the ability
to screen children who initially screened positive (Robins et al., 2014). In Robins (2008), 21 of
362 cases who initially failed the M-CHAT produced a low PPV of .058, yet after follow-up
interview, the screen positives were reduced to 37, bringing the post-follow-up PPV to .57.
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Consequently, some researchers have recommended against using the M-CHAT in low-risk
populations in clinical settings due to the M-CHAT’s low PPV at the first stage of screening
(Baduel et al. 2017). While Baduel et al. (2017) argue that the M-CHAT is not the most suited
tool for screening low-risk populations, Baranek (2015) examined whether Level 1 screening
tools for ASD were effective for detecting autism in the general population at ages 14 to 36
months and concluded that level 1 screening tools were effective in ASD screening (Baranek,
2015). While the sensitivity of the M-CHAT with follow-up was reported as high overall,
generally ranging from .85-0.93, the review from Robins et al. (2014) indicated that higher
sensitivity was dependent on a cut-off score of 3, and any deviation from that cut-off score
resulted in noticeable decreases in sensitivity. The sensitivity of the M-CHAT is generally higher
for children at 30 months of age than at younger ages (Guthrie, 2019). This effect of agedependent sensitivity tenably highlights the need to ensure accurate testing, vetting, and analysis
of the diagnostic accuracy of ASD screening tools used to identify children at young ages and
target them for behavioral intervention.
Despite the high sensitivity of the M-CHAT in the literature (Kleinman, 2008; Robins et
al., 2014; Scarpa et al., 2013), a growing body of evidence indicates that design weakness likely
led to inflations of this metric (Guthrie et al., 2019; Stenberg et al., 2014). Notably, in the U.S.,
Guthrie et al. conducted a large-scale cohort study with long-term follow-up on universal
screening with the M-CHAT/F to assess the tool’s “real-world” accuracy and to assess the
accuracy of repeated screening across four years from age 4 to 8 and examine the effects of child
and family characteristics on screening rates and accuracy (Guthrie et al., 2019). The Guthrie et
al. analysis (2019) demonstrated a lower sensitivity (39%) and PPV (15%) than previously
reported in smaller-scale studies in the United States. Yet, their results validated and agreed with

META-ANALYSIS OF DIAGNOSTIC ACCURACY OF ASD SCREENING TOOLS

18

the diagnostic accuracy results of large-scale longitudinal population studies conducted in
Malaysia (Toh et al., 2018) and Norway (Stenberg et al., 2014). Thus, rigorous assessment of a
diagnostic screening tool for autism must address how the tool performs on population-based
samples comparable to epidemiological prevalence data on autism. When a population-based
sample is unavailable and follow-ups cannot be performed, prevalence data might be used to
adjust metrics to obtain the best estimates for how the screening tool would perform in a realworld setting (Barbaro & Dissanayake, 2010).
1.5

Methodological Quality Assessments
Screening tools are vetted in several ways in practice and academic review. Individual

studies typically come from clinical or university centers that screen children for ASD and then
reassess with monitoring. Follow-up interviews provide valuable information on the diagnostic
accuracy of a tool. However, clinically collected data are often not publicly available, so
formalized reviews are necessary for vetting the diagnostic accuracy of ASD screening tools.
Meta-analyses of screening accuracy effectively vet screening tools for the field by formally
identifying and summarizing evidence on the diagnostic accuracy of screening tests.
Furthermore, meta-analyses document the quality of studies and provide evidence for the quality
of the tests reviewed.
Systematic reviews are a primary method of critically reviewing the scope and quality of
available research on autism screening tools (Sanchez-Garcia et al., 2019; Levy et al., 2020;
Olmstead, 2020; Petrocchi et al., 2020; Desideri et al., 2021; Salgado-Cacho et al., 2021). Setting
the inclusion criteria is the first step in systematic reviews and/or quantitative meta-analyses
(Olmstead, 2020). This step highlights the number of higher quality and lower quality studies
and provides a record of what screening tool studies were reviewed (Øien et al., 2019). Test
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diagnostics across studies are compared, which assess the extent of or lack of reported diagnostic
statistic data, including positive predictive value, negative predictive value, sensitivity,
specificity, true positive and negatives, and false positives and negatives (Akobeng, 2017;
Shreffler and Hueker, 2022).
The review process itself assures quality assurance and inventory reporting of screening
tools and the research that documents the diagnostic accuracy of the tools. For example, formal
reviews of ASD screening tests often use STARD (Standards for Reporting of Diagnostic
Accuracy Studies) and QuaDAS (Quality Assessment of Diagnostic Accuracy Studies)
guidelines for research study quality (Bossuyt et al., 2003). Both STARD and QUADAS
formalize the process of assessing the quality of diagnostic accuracy studies. The QUADAS-2
guidelines are designed to assess the quality of primary diagnostic accuracy studies and consists
of four key domains covering patient selection, index test, reference standard, and flow of
patients through the study and timing of the index test(s) and reference standard (“flow and
timing”) (Table 1). The tool is completed in four phases: 1) state the review question; 2) develop
review-specific guidance; 3) review the published flow diagram for the primary study or
construct a flow diagram if none is reported; 4) judgment of bias and applicability (Whiting et
al., 2003). The STARD (Standards for Reporting Diagnostic accuracy studies) guidelines were
created to assist the transparency and completeness of reporting diagnostic accuracy studies and
help reviewers identify potential sources of bias (Bossuyt, 2003).
Several systematic reviews of autism screening tools survey the current literature and
report on studies that meet the STARD and QuaDAS guidelines while also documenting which
studies were found that scored low on the STARD and QuaDAS guidelines. For example,
Olmstead (2020) reported that up to a quarter of peer-reviewed articles on autism screening tools
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are low quality according to QUADAS guidelines and especially problematic in terms of the
‘flow and timing’ of patient screening where it is difficult or impossible to determine whether
patients who were excluded from the final contingency tables for diagnosis received the index or
reference standard test (Whiting et al., 2003, 2004). Single tool studies that do not use the
STARD or QUADAS may introduce sources of bias that are nearly impossible to identify. If
these studies are then selected for inclusion in a meta-analysis, the analysis may include bias that
is hard to identify and correct. Therefore, using epidemiological prevalence to adjust for false
and true negatives offers one method for adjusting for unknown bias introduced by patient
samples where the true frequency is unknown or unclear (Guthrie et al., 2019; Yuen et al., 2018).
1.6

Issues with Current Approaches to Review and Meta-Analyses of ASD Screening
Tools
There are more issues that should be addressed than those related to frameworks and best

practices. For example, Øien et al. (2019) recently expressed concern over the unanalyzed
heterogeneity across the ASD screening studies included in the Sanchez et al. (2019) metaanalysis. Furthermore, while unanalyzed heterogeneity is a noted problem, more fundamental
concerns exist. For example, the frequency with which studies are reported with missing
diagnostic accuracy data is cause for concern. Missing diagnostic accuracy measures may be one
route by which measurement bias and uncontrolled heterogeneity are introduced into screening
studies and meta-analyses.
In addition to missing data, insufficient attention has been given to the expected
prevalence of ASD in population-based studies (Petrocchi et al., 2020). Although the population
studies are set up as representative studies and provide rigorous screening, comparisons to
epidemiologically derived prevalence estimates are often not central to the study’s tests and

META-ANALYSIS OF DIAGNOSTIC ACCURACY OF ASD SCREENING TOOLS

21

conclusions. Many past studies, systematic reviews, and meta-analyses screen in multiple stages
and first split the population into screened positives and screened negatives prior to their analysis
to determine the total prevalence, and data on false negatives are often impossible to obtain in a
study without extended follow-ups (Kleinman et al.2008; Robins et al., 2014). Additionally,
many validation studies are primarily focused on the clinical application of the screening tools
and therefore focus efforts on positively screened cases and aim to identify those cases that have
ASD from that pool of patients (Baron-Cohen et al., 1996; Robins et al., 2014; Sturner et al.,
2022).
One consequence of focusing on improving the screening of positive cases and the issue
of costs associated with ASD screening is that negative screenings typically do not receive
follow-up assessments (Øien et al., 2019). Lack of follow-up with initial negative screenings
could mask the true FN counts in each sample, as evidenced by recent M-CHAT studies (e.g.,
Guthrie et al., 2019). This increase in FNs may arise when an initial negative screening is later
identified as an ASD case, therefore categorizing that identification as a FN. Collectively, the
lack of attention to FNs can result in screening tools considered adequate until appropriate
follow-up studies prove otherwise. In the case of the M-CHAT, follow-up studies were published
many years after the tool had gained widespread popularity as highly accurate and gained a
foothold in the clinical culture based on overly optimistic analyses. There is clearly a need for
the field to better vet the potential weakness of screening tools.
1.7

Research Purpose of the Current Study
One of the primary methods for scientific fields to determine which tools or methods are

best is to conduct systematic reviews and meta-analyses (Pigott, 2012; Pigott & Polanin, 2020,
Schauer et al., 2022). In the case of screening tools, meta-analyses of diagnostic accuracy
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(MADA) are frequently conducted. Notably, despite the goal of Level 1 screeners as population
level tools, screening studies rarely use population estimates as success benchmarks informing
the accuracy of the screening tool (i.e., estimate potential false negatives). For example, Barbaro
and Dissinayake (2010) concluded that their study's true sensitivity and specificity could not be
calculated due to a lack of follow-up data. To circumvent this design limitation, they compared
their study’s sensitivity and specificity estimates to the expected measures had their population
matched country-specific prevalence (i.e., Australia). Thus, recovering potentially missed case
data and adjusting measures by matching the data source to an epidemiologically reported
prevalence is one potential method study authors could apply to account for and improve the
real-world accuracy of a MADAs to account for the bias that may occur when systematic
reviews and meta-analyses studies do not report on falsely screened subjects, and/or lack
sufficient follow-up. Thus, the potential adjustment to an expected reduction of sensitivity and
overall diagnostic accuracy resulting from epidemiological prevalence adjustment is a primary
focus of this study.
A secondary issue is that systematic reviews and meta-analyses of screening studies
frequently only report data highlighted in original reports and do not attempt to recover missing
data points that can easily be calculated from study level confusion matrices (i.e., false negatives,
false positives, true negatives, true positives) and reported accuracy metrics. This is important as
the omission of data may bias diagnostic accuracy measures, including Se, Sp, PPV, and NPV.
Past meta-analyses have often reported the original study data missing and then excluded those
study metrics from the meta-analyses, which limits the tests of diagnostic accuracy to the subset
of metrics reported (Yuen et al., 2018; Oner et al., 2019; Hoang et al., 2019; Tsai et al., 2019;
Fäldt et al., 2021). Further, some past studies only reported on TP and PPV, which limits the
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assessment of the accuracy of the ability of the screening tool to positively screen children with
autism. The combination of unreported data and the lack of follow-up prevents a true assessment
of falsely screened children (Brooks et al., 2015; Chlebowski et al., 2013; Pierce et al., 2011). As
Guthrie et al. noted, follow-up studies often report lower sensitivity than studies without followup. However, many systematic reviews and meta-analyses typically select studies without
follow-up and consequently report a higher sensitivity than follow-up studies (Guthrie et al.,
2019).
ASD is a complex disorder with a wide range of symptoms and severity. There is no
single “gold standard” test for ASD, and diagnosis is typically based on a combination of clinical
observation, behavioral assessment, and developmental testing. Screening tools for ASD are
designed to identify children who may benefit from further evaluation by a specialist. However,
the accuracy of these tools varies widely, and false-positive and false-negative results are
common. Prevalence estimates of autism spectrum disorder (ASD) vary widely, making it
difficult to compare the accuracy of different screening tools. Meta-analyses are a powerful tool
for pooling data from multiple studies and providing an overall estimate of a phenomenon. A
meta-analysis that adjusts for epidemiological prevalence can provide a more accurate estimate
of the diagnostic accuracy of a screening tool. These estimates can help guide clinicians in using
these tools and improve the accuracy of ASD diagnosis.

The purpose of this study was to conduct an umbrella review and meta-analysis of
diagnostic accuracy (MADA) of autism spectrum disorder (ASD) using previously published
meta-analyses data to evaluate the effect of three missing data and prevalence adjustment
methods on pooled diagnostic accuracy metrics. To investigate how adjusting for
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epidemiological prevalence can provide more real world accurate results, the current study
conducted an umbrella review and meta-analysis of diagnostic accuracy (MADA) of Autism
spectrum disorder (ASD) Level 1 (population level) screening tools for children six and under
with the following three goals: 1) Create a core collection of systematic review studies that
represent the “field norm” for systematic reviews, meta-analyses, and reporting; 2) abstract data
from identified reviews and recover missing (i.e., unreported) data using standard diagnostic
accuracy formulas, then compare MADA results of original and recovered data approaches; 3)
develop adjusted true and false negative rates based on reported ASD epidemiological
prevalence rates to develop adjusted accuracy metrics for each study and compare MADA results
of epi-adjusted with original reports. This study will help answer the following questions: 1)
How much data is missed by field standard systematic review and MADA approaches? 2) Does
recovering missing data substantively change reported accuracy? 3) What is the impact of epiadjustments on implicated diagnostic accuracy? This study investigated whether the prevalence
adjustment method would help the field and interested stakeholders see the ‘real world’
population-level accuracy of ASD screening tools as reported in the literature.

2
2.1

METHODS AND MATERIALS

Selection Criteria and Study Quality Assessment
The current study included papers that focused on ASD screening using the studies that

included the most recently revised tools and earlier versions of the screening tools for
comparison. Reviewed studies were selected from an umbrella review of 6 previously published
systematic reviews and meta-analyses of ASD screening tools (Desideri et al., 2021; Levy et al.,
2020; Petrocchi et al., 2020; Salgado-Cacho et al., 2021; Sánchez-García et al., 2019) that used
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study criteria to vet studies for inclusion and solely focused on children. For example, Levy et al.
(2020) selected their studies based on whether the studies addressed their key research questions,
studies that were not conducted outside the United Nations Development list of countries rated as
“very high human development,” studies that did not include high-risk referral populations, and
studies with a sample size of 100 or more subjects. Additionally, Sanchez-Garcia et al. (2019)
only selected studies that focused on tools designed to screen for ASD, general population-based
screening studies, studies that provided sufficient data to construct a 2 × 2 contingency table of
screening × diagnosis, and those studies that were assessed to have low bias according to the
QUADAS-2 Tool (Quality Assessment of Diagnostic Accuracy Studies-2) criteria (Whiting et
al., 2004). Another selected study described the development and technological delivery of
screening tools and studies with prior quantitative evaluations of diagnostic accuracy (Desideri et
al., 2021).
Most of the selected reviews from the umbrella list of six meta-analyses used PRISMAinformed flowcharts (Olmstead, 2020; Petrocchi et al., 2020; Desideri et al., 2021; SalgadoCacho et al., 2021); all six meta-analyses identified only studies that used validated screening
tools or included previously well validate screening tools, screening tools which were easily
completed by parents or childcare workers, and peer-reviewed articles that included at least one
measure of diagnostic accuracy (Desideri et al., 2021; Levy et al., 2020; Petrocchi et al., 2020;
Salgado-Cacho et al., 2021; Sánchez-García et al., 2019). Where reviews and meta-analyses
included the same studies, this study only included the data from the overlapping studies once
(Appendix B). All prior review study data was extracted from the original papers by hand or
using Power BI table extraction, and data was condensed into a flat data table to facilitate data
analysis. All studies were published between 1996 and 2020, and only studies published in
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English were used. Studies were selected if the original inclusion age fell between 12 and 60
months, although some studies feature children as young as 10 months, and one study included
children who were 73 months (6 years) of age.
The literature search for potential reviews and MADA studies to include in the umbrella
review used the following search engines: EBSCO, Proquest, Web of Science, Google Scholar,
and Medline. The search terms included the following variations of “autism”: “autistic”;
“developmental disorder”; “Aspergers”; “pervasive developmental disorders”; “PDD”; “screen”;
“screening”; “Level 1”; “assessments”; “early identification”; “early detection”; “early
diagnosis”; “early diagnosis”; “early prediction”; “population” AND “review”; “reviews”;
“meta-analysis”; and “meta-analyses.” A summary flowchart of study selection based on the
original six meta-analyses is shown below in Figure 2 (Desideri et al., 2021; Levy et al., 2020;
Petrocchi et al., 2020; Salgado-Cacho et al., 2021; Sánchez-García et al., 2019).
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Summary Flowchart

Across reviews, a total of 79 studies were initially identified and then deemed eligible if
the studies were population-based, or Level 1, studies and included (but not limited to) the
following: At least one measure of diagnostic accuracy (such as sensitivity, specificity,
predictive values, or AUC); a structured study design describing the methods, results, and
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conclusions in the abstract; an introduction that included scientific and clinical background,
including the intended use and clinical role of the index test; detailed data collection protocols;
eligibility criteria; studies that reported measures of diagnostic accuracy; a flow diagram of
participant selection and screening stages (Desideri et al., 2021; Levy et al., 2020; Petrocchi et
al., 2020; Salgado-Cacho et al., 2021; Sánchez-García et al., 2019). After reviewing the nonoverlapping selection of studies (n = 57), this study selected a final sample size of 28 previously
reviewed population-level studies for inclusion (total screened = 205,934).
2.2

Study Variables
The primary data considered included positive and negative screening results from

studies identified in each autism systematic review and meta-analysis we selected for the
umbrella review: true positives (TP), true negatives (TN), false positives (FP), and false
negatives (FN). Furthermore, study-specific diagnostic accuracy measures derived from the
confusion matrix of positives and negatives were included or recovered and calculated where
missing. Diagnostic accuracy metrics include sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV).
2.3

Data Extraction
Data were extracted from the tables from each study and included the crude values for

true positive (TP), true negative (TN), false positive (FP), and false negative (FN). Furthermore,
the reported psychometric properties of sensitivity (Se), specificity (Sp), positive and negative
predictive values (PPV, NPV), positive and negative likelihood ratio values (LR+; LR−), and the
diagnostic odds ratio (DOR) were recorded. The following data was also included in the final
data table: author name; year of publication; the country where children were sampled; and the
original total population sample size and the study sample size.
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Data Approaches
In total, this meta-analysis tests prior study data by comparing four approaches:
1. Original data in situ, including data reported with missing values.
2. Original data with the missing data algebraically calculated and recovered.
3. Study data with missing recovered adjusted for national prevalence by year (Chiarotti
& Venerosi, 2020).
4.

Study data with missing recovered adjusted using the most recent CDC surveillance
data (Maenner et al., 2021) (Table 3).

2.4.1

Original Data

The original data approach used the diagnostic accuracy results in data extracted from
tables from the six original meta-analyses, in situ, with no attempts to recover data when it was
missing. In cases when software functions would not accept data with missing values, only
complete cases of the original data were used.
2.4.2

Recovering Missing Data

Missing data occurs frequently in diagnostic accuracy studies, but missing data are easily
calculated and recovered. For the data recovery approach, we used available data reported across
studies and used standard formulas to estimate missing True Positive (TP), True Negative (TN),
False Positive (FP), and FN data points. For example, Table 1 contains a confusion matrix
indicating data required to calculate sensitivity, specificity, Positive Predictive Value (PPV), and
Negative Predictive Value (NPV), commonly reported in screen tool accuracy studies. These
standard diagnostic accuracy formulas can be used to recover missing data not reported in
original studies.
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Missing data is common in all forms of analyses, and numerous statistical approaches
have been developed to predict missing data values (Schauer, Diaz, Pigott, & Lee, 2022).
According to Schauer et al. (2022), estimates quantifying bias show that the omission of missing
data increases the bias measures to large magnitudes (Cohen’s D of .4-.8). In the case of missing
elements of diagnostic accuracy, predictive modeling is not always necessary and basic algebra
can be used to estimate the missing data points working from a particular study’s TP, TN, FP,
FN elements, sample size information, and the diagnostic accuracy metrics reported. The current
study recovered this missing data algebraically using the formulas below in Table 2. All missing
data points were recovered using the missing data formulas listed in Table 4 sequentially so that
once one measure was recovered, the first recovered data was then used to recover additional
missing data. A subset of the missing data solutions that may be derived is illustrated in an
example case in Table 3 using data from Seif-Eldin (2008). For example, Seif-Eldin (2008)
reported the TP and TN from the confusion matrix for their study of the diagnostic accuracy of
the M-CHAT, where they did not report on the FP and FN values.
Table 2
Commonly Reported Diagnostic Accuracy Metric Formulas
Missing data point
Formula
Missing TP calculated
if sensitivity and FN
are known sensitivity
= TP/(TP+FN)
Missing TP calculated
if PPV and FP are
known PPV = TP/(TP
+FP)
Missing FN calculated
if sensitivity and TP

Missing data formula worked out

R Script

sensitivity *(TP + FN) = TP
sensitivity *TP + sensitivity *FN = TP
sensitivity *FN = TP - sens*TP
sensitivity *FN = TP*(1- sensitivity)
(sensitivity *FN)/(1- sensitivity) = TP
PPV*(TP + FP) = TP
(PPV*TP) + (PPV*FP) = TP
PPV*FP = TP - (PPV*TP)
PPV*FP = TP*(1 - PPV)
(PPV*FP)/(1-PPV) = TP
(TP + FN)*sensitivity = TP
TP*sensitivity + FN*sensitivity = TP

dataFrame$tpSensFn <
((dataFrame$Sensitivity*dataFrame$FN)/
(1 - dataFrame$Sensitivity))
dataFrame$tpPpvFp <((dataFrame$PPV*dataFrame$FP)/(1 dataFrame$PPV))
dataFrame$fnSensTp <(dataFrame$TP*(1 -
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are known sensitivity
= TP/(TP+FN)
Missing FN calculated
if NPV and TN are
known NPV = TN/(TN
+FN)
Missing FP calculated
if specificity and TN
are known specificity
= TN/(FP + TN)
Missing FP calculated
if PPV and TP are
known PPV= TP/(TP
+ FP)
Missing TN calculated
if specificity and FP
are known specificity
= TN/(TN + FP)
Missing TN calculated
if NPV and FN are
known NPV = TN/(TN
+ FN)

FN*sensitivity = TP - (TP*sensitivity)
FN*sensitivity = TP*(1 - sensitivity)
FN = TP(1- sensitivity)/sensitivity
NPV*(TN + FN) = TN
(NPV*TN) + (NPV*FN) = TN
NPV*FN = TN - (NPV*TN)
NPV*FN = TN*(1 - NPV)
FN = TN(1-NPV)/NPV
specificity*(FP + TN)
specificity*FP + specificity*TN = TN
specificity*FP = TN - specificity*TN
specificity*FP = TN*(1 - specificity)
FP = TN(1 - specificity)/specificity
PPV*(TP + FP) = TP
PPV*TP + PPV*FP = TP
PPV*FP = TP - PPV*TP
PPV*FP = TP*(1 - PPV)
FP = TP(1 - PPV)/PPV
specificity*(TN + FP) = TN
specificity*TN + specificity*FP = TN
specificity*FP = TN - specificity*TN
specificity*FP = TN*(1 - specificity)
specificity*FP/(1 - specificity) = TN
NPV*(TN + FN) = TN
NPV*TN + NPV*FN = TN
NPV*FN = TN - NPV*TN
NPV*FN = TN*(1 - NPV)
NPV*FN/(1 - NPV) = TN
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dataFrame$Sensitivity)/dataFrame$Sensit
ivity)
dataFrame$fnNpvTn <(dataFrame$TN*(1 dataFrame$NPV)/dataFrame$NPV)
dataFrame$fpSpecTn <(dataFrame$TN*(1 dataFrame$Specificity)/dataFrame$Speci
ficity)
dataFrame$fpPpvTp <(dataFrame$TP*(1 dataFrame$PPV)/dataFrame$PPV)
dataFrame$tnSpecFp <(dataFrame$Specificity*dataFrame$FP)/(
1 - dataFrame$Specificity)
dataFrame$tnNpvFn <(dataFrame$NPV*dataFrame$FN)/(1 dataFrame$NPV)

Table 3
Seif-Eldin Missing Values
FP given TP and PPV
FP = TP(1-PPV)/PPV =
122 * (1- .89)/0.89 = 15

2.4.3

FN given TP and Sensitivity
FN = TP(1- Se)/Se =
122 * (1 – .86) /0.86 = 20

Population Adjusted Negatives Screens and Resulting Accuracy Scores

A non-technical population prevalence-adjusted approach to abstracted study data was
recently reported in a MADA of ASD screening tools showing how missed cases might impact
reported sensitivity (Olmstead, 2020). To do this, first, we identified ASD prevalence rates based
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on the national ASD prevalence closest to the year of publication (Chiarotti & Venerosi, 2020;
IMHE, 2018) and the prevalence rates published by the CDC for the years 1992-2018 across 11
sites from the Autism and Developmental Disabilities Monitoring Network (ADDM) (e.g.,
Maenner et al., 2021). Pop-adjusted accuracy metrics were then developed for each identified
study by determining the expected ASD cases within a sample dependent on the nation’s
prevalence or the CDC prevalence rates for 1992-2018, resulting in population-adjusted TN and
population-adjusted FP metrics.
Pop-adjusted sensitivity was then developed from the original TP and the populationadjusted TN. The epidemiological adjustments based on national and CDC prevalence (Table 4)
were calculated by taking the product of the study population estimate (calculated as a proportion
of the TP cases to the complete study sample size) and the prevalence of ASD for the year and
national origin (IMHE 2018) of the original study (National Approach), and the year of the study
matched with the closest year of the CDC prevalence reported from the ADDM (CDC, 2021).
After calculating the prevalence adjustment, one may develop a metric to describe the potentially
missed ASD cases with the following equation:
adjPrevalenceN = Population Estimate Prevalence * Study Analyzed Sample Size
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 − (𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹)

Adjusted FN = Potentially Missed Cases + FN (from original report)
Adjusted TN (from original report) = TN (from original report) - Potentially Missed
Cases
Pop-adjusted Sensitivity = TP (original report)/(TP [original report] + Adjusted FN)
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Table 4
Data Approaches Used in the Meta-Analyses
Approach

Adjustment

N

Original data
(Missing data)

None

Recovered Data

Missing diagnostic measures were
algebraically recovered

28

Adjusted for prevalence from the
nation and year of origin

28

Nationally Adjusted
CDC Adjusted

28/20*

Adjusted for prevalence from the CDC
ADDM year of origin

28

* Multivariate analyses with MADA package required the omission of cases.
Studies identifying more cases than indicated by population adjustments retained the
originally reported FN and TN. When studies did not report data points for FN or TP, these
missing values were calculated from the data that was available using the standard diagnostic
accuracy formulas algebraically to solve for ‘x’ (Tables 1 & 3). For example, both SanchezGarcia et al. (2019) and Olmstead (2020) cited a study from Chlebowski et al. (2013) that
reported data on 18,446 children 18 to 24 months on the M-CHAT/R with a calculable sensitivity
of ~94% [92/(92 + 6)*100]. The example below used CDC's (2021) national prevalence to
estimate the potentially missed cases for the Chlebowski et al. (2013) sample.

1/68 (CDC 2012 Population Estimate) = x/18,446 (Study Sample)
x = ~ 271 expected ASD cases in a Study Sample
Potentially Missed Cases: 271 – (92 + 6) = 173
Adjusted FN: 173 + 6 = 179
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Adjusted TN: 18269 – 173
Pop-adjusted sensitivity = ~34% [92/(92 + 179)*100].
2.5

Statistical Analysis
A multivariate analysis with random effects was chosen a priori, yet univariate analyses

are included for descriptive purposes. Random effects were used to allow the effect sizes of
different screening tools and screening populations to vary (Borenstein et al., 2009; Reitsma,
2005). First, a univariate descriptive analysis was run using the confusion matrix of TP, TN, FP,
and FN to get pooled results for the diagnostic accuracy measures based on the original data and
report on the χ2 test of equalities of sensitivity and specificity. Following the univariate analysis,
this study conducted a multivariate analysis of the confusion matrix variables using a bivariate
Reitsma model approach (Reitsma et al., 2005). The decision to use both univariate and
multivariate analysis was chosen a priori. The bivariate model to account for unknown sources
of potential bias introduced when samples include different sample sizes and screening methods
and to control for the joint effect of specificity and FPR on sensitivity and estimate diagnostic
accuracy (Reitsma et al., 2005). A Hierarchical Summary Receiver Operating Characteristic
Model (HSROC) (Rutter and Gatsonis 2001) was used to generate summary receiver operating
characteristic curves and plotted to compare variation in sensitivity and false positive rates across
studies and the four data approaches described previously. The R package MADA was used for
all statistical analyses and figure creation (Doebler & Holling, 2015).
This study assessed the heterogeneity of diagnostic odds ratios with a visual inspection of
the SROC plots and by using Cochran’s Q test (Cochran 1954) and random DerSimonian
estimated summary DORs–Laird model (DerSimonian and Laird 1986) described previously in
Macaskill et al., (2010) given the a priori decision to use bivariate and multivariate analyses
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given the assumption of heterogeneity. Heterogeneity was tested post hoc and deemed present
when the I2 statistic was greater than .50 and the Cochran Q p < 0.1. Next, this research
investigated bivariate heterogeneity and carried out subgroup analyses using the method of
approach as the independent variable. Finally, this study summarized the confidence intervals of
Se and FP cases in each study using a crosshair plot and ROC ellipses plot with the R-package
meta-analysis of diagnostic accuracy (MADA) (Doebler 2015). All summary diagnostic
accuracy and model measures were calculated using R (Doebler, 2015).
2.5.1

Comparisons of Diagnostic Accuracy Across Approaches

The next steps in the analysis included a comparison of differences across approaches
first by using a non-parametric test for establishing meaningful differences in pooled Se, FPR,
and DOR, then using metaregression to compare models for Se and FPR across approaches.
According to the evidence in Barbaro and Dissinayake (2010) and Guthrie et al. (2019),
adjusting the original study data for epidemiological prevalence would decrease sensitivity,
which downstream lowers DOR and would also result in a difference in the FPR. Differences in
Se, DOR, and FPR among the data approaches were examined first with a non-parametric
omnibus test using the Kruskal-Wallis test, then followed by a paired Wilcoxon Rank Sum test
for planned comparisons of Se, DOR, and FPR between each pair of data approaches. The
Kruskal-Wallis test is the preferred non-parametric alternative to the ANOVA and an extension
of the Mann-Whitney test (Ostertagová et al., 2014) and was used in this study as an omnibus
test for explained variance in differences in Se, FPR, and DOR among the original meta-analysis
data and the three data adjustment approaches. Next, we conducted planned comparisons of
differences in Se, FPR, and DOR measures of each data source approach using the Dunn
multiple comparisons test for pairs of the data approaches. The last stage of the analysis used the
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Reitsma function to run metaregression tests comparing Se and FPR first without covariates to
derive overall pooled estimates of Se and FPR, then with covariates for screening test type and
nation of origin tested with each data approach.

3
3.1

RESULTS

Study Characteristics
Across the six reviews, 57 unique studies were considered for analysis. Of these, 28 fit

the inclusion criteria. The total starting population sample analyzed included 131,738 children
ages 6 to 72 months (Table 5). Among the final 28 studies, 20 were conducted in the US
(71.43%), and eight were conducted outside the US (28.57%).
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Table 5
Study Characteristics
Study

Year

Test

Country

Age

N

Total N

Baduel FUI

2016

M-CHAT

France

18 to 24

1,227

1,250

Baranek NEW

2015

M-CHAT

USA

24

574

574

Baron-Cohen et al.

1996

CHAT

UK

18

50

16000

Canal-Bedia

2011

Spain

18 to 36

2,055

2,480

Chlebowski

2013

M-CHAT
M-CHAT
/ Yale / STAT

USA

0 to 36

18,446

18,989

Cuesta-Gomez

2016

M-CHAT

Argentina

18 to 30

404

420

Dereu

2010

CESDD

Belgium

3 to 39

6,808

6,808

Dietz

2006

ESAT

Netherlands

14 to 15

255

31,724

Fäldt

2021

ITC

Sweden

18

679

704

Hoang

2019

M-CHAT

Vietnam

16 to 36

17169

17754

Honda 2005

2005

YACHT-18

Japan

18

35,716

35,716

Inada

2011

M-CHAT - full

Japan

18

1,167

1,187

Kamio

2014

MCHAT_JV

Japan

16 to 31

1,727

2,141

Kerub

2018

M-CHAT

Israel

18 to 24

1591

1591

Kondolot

2016

M-CHAT

Turkey

10 to 16

2021

2021

Magan-Maganto

2018

M-CHAT-R/F

Spain

12 to 47.5

3506

3529

Miller

2011

ITC _+ M-CHAT

USA

14 to 30

667

796

Nygren

2012

M-CHAT

Sweden

30 to 35

3,985

3,999

Oner & Munir

2019

Turkey

16 to 30

6483

6712

Pierce

2011

M-CHAT-R/F
CSBS-DP-ITChecklist

USA

12 to 24

450

10,479

Sturner

2016

M-CHAT F

USA

18 to 24

4,830

5,071

Sun et al.

2015

Mandarin CAST

China

714

737

Toh

2018

M-CHAT

Malaysia

27 to 36

19297

22358

Topcu

2018

M-CHAT

Turkey

18 to 47

511

1345

Turner-Brown

2012

FYI - 60

USA

16 to 30

699

1192

VanDenHeuvel

2007

M-CHAT-R/F

Ireland

18

2117

2684
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Wetherby

2008

ITC

USA

6 to 24

1,274

5,385

Zahorodny

2018

PDQ-1

USA

18 to 24

1,959

2,288

3.2

Missing Data Recovery
Many original studies had missing data, and none of the reviews attempted to address

missing data in their analyses. Of 28 studies included in this umbrella review and meta-analysis,
23 directly reported TN (17.86% missing), and 25 reported false positives (10.71% missing). Out
of 28 studies included, 24 directly false negatives (14.29 % missing). All the included studies
reported true positives (TP). Only 20 of 28 studies reported sensitivity (28.6% missing), 21 of 28
studies reported specificity (25% missing), 23 reported PPV (17.86% missing), and 15 of 28
studies reported NPV (46.4% missing).
3.3

Descriptive Analysis

Original
The results of the descriptive statistics analysis for the contingency measures are shown
in Table 6 below. The mean, median and range for the original study data confusion matrix
measures were as follows: TP (M = 26, Mdn = 18, Range =1-129); TN (M = 4151, Mdn = 1930,
Range = 1-19259); FP (M = 39, Mdn = 21, Range = 1-265); and FN (M = 7, Mdn = 4, Range =
0-32). The mean sensitivity for the original with missing data was .80, and the other unweighted
means for the other diagnostic accuracy measures were as follows: Spec (.94); PPV (.41); and
NPV (0.98) before missing data was recovered (See Table 6). The range in reported sensitivity
was large, spanning from .44 to a sensitivity of 1. Thus, the average sensitivity, specificity,
positive predictive value (PPV), and negative predictive value (NPV) suggests that the tests
overall performed better at screening out negative ASD cases (Spec: M = .94, NPV: M = 0.98)
than detecting ASD cases (Sens: M = .8, PPV: M = .41).
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Recovered Data
The results of the descriptive statistics analysis for the contingency measures are shown
in Table 6 below. The mean, median and range for the recovered study data source for the
confusion matrix measures were as follows: TP (M = 26, Mdn = 18, Range =1-129); TN (M =
4063, Mdn =1796, Range = 1-19259); FP (M = 574, Mdn =22, Range = 0-15005); and FN (M =
12, Mdn =4, Range = 0-147). The mean sensitivity for the recovered data approach was .79, and
the other unweighted means for the other diagnostic accuracy measures were as follows: Spec
(.91); PPV (.39); and NPV (.95) after missing data was recovered (See Table 6). The range in
reported sensitivity was large and matched the missing data source, spanning 0.18 to a sensitivity
of 1.0.
Nationally Adjusted Data
The results of the descriptive statistics analysis for the contingency measures are shown
in Table 6 below. The mean, median and range for the nationally adjusted data source for the
confusion matrix measures were as follows: TP (M = 26, Mdn = 18, Range =1-129); TN (M =
4054, Mdn = 5912, Range = 1-19232); FP (M = 574, Mdn = 22, Range = 0-15005); and FN (M =
22, Mdn = 6, Range = 0-189). The mean sensitivity for the nationally adjusted data was .64, and
the other unweighted means for the other diagnostic accuracy measures were as follows: Spec
(.28), PPV (.42), and NPV (.96) (Table 6). The range in reported sensitivity was large and
increased over the missing and recovered data sources, spanning .14 to a sensitivity of 1.
CDC Adjusted Data
The results of the descriptive statistics analysis for the contingency measures are shown
in Table 6 below. The mean, median and range for the CDC adjusted data source for the
confusion matrix measures were as follows: TP (TP (M = 26, Mdn = 18, Range =1-129); TN (M
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= 4013, Mdn =1787, Range = 0-18871); FP (M = 574, Mdn = 22, Range = 0-15005); and FN (M
= 62, Mdn = 23, Range = 0-420). The mean sensitivity for the nationally adjusted data was .42,
and the other unweighted means for the other diagnostic accuracy measures were as follows:
Spec (.28), PPV (.42), and NPV (.87) (Table 6).
Comparison of Approaches
The unweighted means for sensitivity (Se) decreased for the recovered (M = .79),
nationally adjusted approach (M = .64), and CDC adjusted data approach (M = .42) relative to
the Se in the original data source with missing data (M = .80). Positive predictive value (PPV)
decreased when missing data (M = .41) was recovered. All 28 samples were analyzed (M = .39),
then increased to .42 with the adjustments for national and CDC reported prevalence. The
unweighted means for Sp (M = .94) decreased dramatically after adjustments from the national
prevalence approach (M = .28) and the CDC reported prevalence approach (M = .28).
Recovering missing data and using all 28 studies decreased Sp less than the epidemiological
prevalence adjustments (M = .91). The negative predictive value (NPV) decreased slightly for
the recovered data (M = .95) relative to the same measures from the originally reported data with
missing values (M = .98). The reduction in NPV was the least in the nationally adjusted data
approach (.96). The largest decrease in NPV was present in the CDC adjusted data approach
(.87).

Table 6
Descriptive Statistics for the Diagnostic Accuracy Measures Original Data then Recovered,
Nationally Adjusted, and CDC Adjusted Data
Measures
Missing

n

Mean

SD

SE

Median

Min

Max

Range

% Missing
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TP

28

25.75

29.87

5.64

18

1

129

128

0%

TN

23

4150.87

5861.37

1222.18

1930

1

19259

19258

17.86%

FP

25

39.2

55.43

11.09

21

1

265

264

10.71%

FN

24

7.33

9.09

1.85

3.5

0

32

32

14.29%

Se

26

.80

.18

.03

.84

.44

1

.56

7.14%

Sp

25

.94

.10

.02

.98

.59

1

.41

10.71%

PPV

27

.41

.29

.06

.34

.07

1

.93

3.57%

NPV

24

.98

.07

.01

1

.68

1

.32

14.29%

N

28

4704.93

7509.39

1419.14

1659

50

31073

31023

0%

Total N

28

7354.79

9664.08

1826.34

2582

420

35716

35296

0%

TP

28

25.75

29.87

5.64

18

1

129

128

0%

TN

28

4062.82

5930.76

1120.81

1795.5

1

19259

19258

0%

FP

28

573.89

2828.74

534.58

21.5

0

15005

15005

0%

FN

28

12.14

27.84

5.26

3.5

0

147

147

0%

Se

28

.79

.21

.04

.84

.18

1

.82

0%

Sp

28

.91

.13

.02

.97

.52

1

.48

0%

PPV

28

.39

.30

.06

.3

0

1

.99

0%

NPV

28

.95

.13

.03

1

.47

1

.53

0%

N

28

4704.93

7509.39

1419.14

1659

50

31073

31023

0%

Total N

28

7354.79

9664.08

1826.34

2582

420

35716

35296

0%

TP

28

25.75

29.87

5.64

18

1

129

128

0%

TN

28

4053.29

5912.47

1117.35

1795.5

1

19232

19231

0%

FP

28

573.89

2828.74

534.58

21.5

0

15005

15005

0%

FN

28

21.68

43.82

8.28

5.5

0

189

189

0%

Se

28

.64

.26

.05

.67

.14

1

.86

0%

Sp

28

.28

.25

.05

.21

.01

1

.99

0%

PPV

28

.42

.27

.05

.43

0

1

1

0%

NPV

28

.96

.12

.02

1

.5

1

.5

0%

N

28

4704.93

7509.39

1419.14

1659

50

31073

31023

0%

Total N

28

7354.79

9664.08

1826.34

2582

420

35716

35296

0%

TP

28

25.75

29.87

5.64

18

1

129

128

0%

TN

28

4013.14

5845.7

1104.73

1786.5

0

18871

18871

0%

FP

28

573.89

2828.74

534.58

21.5

0

15005

15005

0%

FN

28

61.96

96.06

18.15

23

0

420

420

0%

Se

28

.42

.28

.05

.36

.04

1

.96

0%

Recovered

Nationally
Adjusted

CDC
Adjusted
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Sp

28

.28

.25

.05

.21

.01

1

.99

0%

PPV

28

.42

.27

.05

.43

0

1

1

0%

NPV

28

.87

.57

.11

.99

-2

1

3

0%

N

28

4704.93

7509.39

1419.14

1659

50

31073

31023

0%

Total N

28

7354.79

9664.08

1826.34

2582

420

35716

35296

0%
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1. Univariate Test for Heterogeneity
The madad function was used to calculate diagnostic accuracy measures under the
assumption of equal variances across TP, TN, FP, and FN measures. Two χ2 tests were produced
to test the equality of sensitivities and specificities between studies. The results of the chi-square
tests for heterogeneity in sensitivity and specificity across the study samples are below (Table 7).
All results were reported as significant and systematically increased with each data adjustment,
starting with recovering missing data, adding a national prevalence adjustment, and then a CDC
prevalence adjustment.
Sensitivity
The original study data with missing values resulted in the lowest test statistic for the test
for equality of sensitivities (χ2= 209.764, p < .0001). The largest increase in the χ2 statistic
between any approach was between the missing data approach and the recovered data approach
(χ2= 435.076, p < .0001). The national prevalence adjusted data using ASD prevalence from the
nation of origin and the year closest to the year of publication only increased slightly over the
recovered data approach (χ2= 479.214, p < .0001). The CDC prevalence-adjusted approach (χ2=
480.345, p < .0001) using prevalence rates published from the CDC for the years 1992-2018
across 11 sites from the Autism and Developmental Disabilities Monitoring Network (ADDM)
(Maenner et al., 2021) increased slightly over the nationally adjusted approach. All data
approaches showed evidence of variance in reported sensitivity and specificity.
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Table 7
χ2 Test for heterogeneity of sensitivities and specificities between studies

Se

Sp

3.4

Approach

χ2 Statistic

Df

p

Original

209.764

19

<.0001

Recovered Data

435.076

27

<.0001

Nationally Adjusted

479.214

27

<.0001

CDC Adjusted

480.345

27

<.0001

Original

1369.625

19

<.0001

Recovered Data

49062.300

27

<.0001

Nationally Adjusted

49313.191

27

<.0001

CDC Adjusted

48769.849

27

<.0001

Univariate Analysis of Diagnostic Accuracy Measures
The descriptive statistics analysis was followed by the univariate analysis of meta-

analysis of diagnostic accuracy (MADA). The univariate summary of diagnostic accuracy
measures was calculated with the madad function from the MADA package in R. The mean Se,
Sp, DOR, FPR, and correlation between Se and FPR for each data approach are summarized in
Table 8 below and visualized as a bar chart with confidence intervals (Figure 3). Forest plots of
sensitivity and specificity were generated with a summary plot for the recovered data approach
(Figures 4 and 5), for the nationally adjusted approach (Figures 6 and 7), and the CDC adjusted
approach (Figures 8 and 9).
Original
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The results in Table 8 below show the pooled diagnostic accuracy measures for the
original studies with missing data, the recovered data, the data with adjustment for national
prevalence by year, and the data with adjustment for CDC reported prevalence for the years
covered in the original studies (1996-2021) (See Table 8). The mean sensitivity for the original
studies with missing data was .721 (95% CI [.546, .826]), and the mean specificity for the
original study data was .947 (95% CI [.928, .960]). The false positive rate (FPR) for the original
missing data samples was .053 (95% CI [.040, .072]). The DOR was 1325.4 (95% CI [316.167,
9423.327]) and the correlation between Se and FPR was -.094 (p = .595).
Recovered Data
The mean sensitivity for the recovered data sample was .743 (95% CI [.563, .843]), and
the mean specificity for the original study data was .917 (95% CI [.879, .941]). The false positive
rate (FPR) for the original missing data samples was .083 (95% CI [.059, .121]). The DOR was
1354.989 (95% CI [319.399, 8940.989]) and the correlation between Se and FPR was .001 (p =
.994).
Nationally Adjusted Data
The mean sensitivity for the national population-adjusted data sample was .683 (95% CI
[.521, .798]), the mean specificity was .917 (95% CI [.879, .941]). The false positive rate (FPR)
for the original missing data samples was .083 (95% CI [.059,.121]). The DOR was 1203.388
(95% CI [ 288.433, 7020.946]) and the correlation between Se and FPR was -.024 (p = .868).
CDC Adjusted Data
The mean sensitivity for the national population-adjusted data sample was .534 (95% CI
[.407, .650]), the mean specificity was .912 (95% CI [.876, .940]). The false positive rate (FPR)
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for the original missing data samples was .088 (95% CI [.060, .124]). The DOR was 291.054
(95% CI [ 101.416, 954.016]) and the correlation between Se and FPR was .223 (p = .124).
Comparison of Approaches
The pooled Se increased for the recovered (Se = .732), then decreased for the nationally
adjusted (.628) and CDC adjusted data approach (Se = .422) relative to the pooled Se in the
original data source with missing data (Se = .723). The side-by-side comparisons of Se and FPR
of each data approach are shown in Figure 3. The pooled Sp of the original missing data
approach (M = .983, 95% CI [0.975, 0.988]) decreased with each step starting with the recovered
data approach (M = .928, 95% CI [0.884, 0.952]) and then decreased in the national prevalence
approach (M = .9279, 95% CI [0.883, 0.952]) and then decreased by a larger magnitude in the
CDC adjusted approach (M = .919, 95% CI [0.878, 0.951]) (See Table 8). Pooled Se
systematically decreased (Table 8, Figures 4, 6, and 8), while Sp decreased more at once, with
very little variation in study sensitivities (Figures 5, 7, and 9).
The pooled diagnostic odds ratio (DOR) decreased dramatically from the missing data
approach (DOR = 1709.797, 95% CI [340.346, 14583.40]) with each data approach applied. The
recovered data DOR decreased (DOR = 1277.462, 95% CI [247.300, 11402.18]), the nationally
adjusted approach DOR decreased (DOR = 1012.16, 95% CI [193.109, 8042.103]) and the
largest drop in DOR occurred after the CDC adjusted approach (DOR = 120.096, 95% CI
[41.230, 435.127]). The correlation between Se and FPR was small but negative in the missing
data approach (r = -.212, p = .369). The correlation between Se and FPR was small to moderate
and positive in the CDC adjusted data (r = .292, p = .131), yet the correlation was not significant.
The correlation between Se and FPR was small in the recovered data approach (r = .106, p =
.591) and there was no correlation in the nationally adjusted approach (r = .009, p = .965). The
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range of confidence intervals for Se and FPR in each data approach is more distinct and larger
after recovering missing data and adjusting for national and CDC prevalence (Figure 3).

Table 8
Univariate Comparison of Diagnostic Accuracy Measures by Approach Original study data with
missing values, recovered data, national prevalence adjusted, and CDC prevalence adjusted
data
CDC Adjusted

0.732

Nationally
Adjusted
0.628

[.493, .847]

[0.513, 0.844]

[0.440, 0.765]

[0.293, 0.554]

Specificity

0.983

0.928

0.9279

0.919

(95% CI)

[0.975, 0.988]

[0.884, 0.952]

[0.883, 0.952]

[0.878, 0.951]

FPR (95%
CI)

0.017

0.072

0.072

0.081

[0.012, 0.025]

[0.048, 0.117]

[0.048, 0.117]

[0.049, 0.122]

DOR (95%
CI)

1709.797

1277.462

1012.16

120.096

[340.346,
14583.40]

[247.300, 11402.18] [193.109,
8042.103]

[41.230, 435.127]

Se ~ FPR

-0.212, p = .369

.106, p = .591

.292, p = .131

Se (95% CI)

Missing

Recovered

0.723

.009, p = .965

0.422
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Figure 3
Mean Sensitivity and FPR, and Crosshair Plots of Se and FPR Confidence Intervals
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Figure 4
Forest Plot of Sensitivities for all studies (Recovered Data Approach)
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Figure 5
Forest Plot of Specificity for all studies (Recovered Data)
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Figure 6
Forest Plot of Sensitivity for all studies (Nationally Adjusted)
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Figure 7
Forest Plot of Specificity for all studies (Nationally Adjusted)

51

META-ANALYSIS OF DIAGNOSTIC ACCURACY OF ASD SCREENING TOOLS
Figure 8
Forest Plot of Sensitivity for all studies (CDC Adjusted)

52

META-ANALYSIS OF DIAGNOSTIC ACCURACY OF ASD SCREENING TOOLS

53

Figure 9
Forest Plot of Specificity for all studies (CDC Adjusted)

3.5

Bivariate Analysis
The results of Cochran’s Q using the DerSimonian–Laird model (DSL) method to test for

heterogeneity of DORs in each approach confirmed that each data approach provided no
statistically meaningful evidence of heterogeneity across studies. Although no direct comparison
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of differences in Cochran’s Q test statistics was tested descriptively, the Q test statistic increased
after the data was recovered and epidemiologically adjusted. The nationally adjusted data source
received the lowest Q statistic (Q = 13.19, p = .988), and the recovered data source produced the
largest statistic (Q = 20.304, p = .818). The CDC adjusted data produced a result (Q = 15.801, p
= .957) lower than the original data source (Q = 19.185, p = .445). The Higgin’s I2 statistic was 0
or near 0 (Original I2 = .963%) for all data approaches denoting no heterogeneity in measures
(Table 9). The measure for between-study variance in random effects models is Tau2, as shown
in Table 9. Among the approaches, the Tau2 statistic was the largest in the nationally adjusted
data approach (tau2 = 10.433).
After an additional review of the literature critiquing the high type one error rate in the
DSL method (Mathes & Kuss, 2018; Röver et al., 2015; Veroniki et al., 2019), we ran a
confirmatory post-hoc heterogeneity test using the R package metaphor specified the same as
before and applied the Hartung-Knapp-Sidik-Jonkman (HKSJ) correction. After applying the
HKSJ correction (Röver et al., 2015), Cochran’s Q results for all data approaches were
significant, indicating meaningful heterogeneity between study DOR outcomes (See Appendix
D).

Table 9
Cochran’s Q, Tau2 and I2
Data Approach

Q

I2

Tau2

Q p-value

df

Original with Missing Data

19.185

.963%

3.369

20.304

6.697

19

Recovered Data

0%

.445

13.19

CDC Adjusted Data

15.801

10.433 .988
5.033 .957

27

Nationally Adjusted Data

0%

.818

0%

27
27
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Pooled diagnostic accuracy measures were calculated using the Reitsma function and
reported below (Table 10). The mean Se, Sp, DOR, FPR, and correlation between Se and FPR
for each data approach are summarized below (Table 10) and visualized as a bar chart with
confidence intervals (Figure 10).
Original
The diagnostic accuracy results for each data approach are reported in Table 10. The
pooled Se from the missing data source was .752 (95% CI [.617, .852]). The Sp for the missing
data source was .99. The FPR in the missing data source was .010 [.006, .017]). The pooled
weighted DOR for the missing data source was 336.55.
Recovered Data
The positive screening-based diagnostic accuracy metrics of the recovered data approach
showed that metrics improved slightly by recovering missing data in magnitude and terms of
narrower confidence intervals. The pooled sensitivity from the recovered data approach was .759
(95% CI [.646, .845]). The FPR in the recovered data approach was .021 [.011, .04]). The pooled
weighted DOR for the recovered data approach was 163.38, and the Sp for the recovered data
was .979.
Nationally Adjusted Data
The nationally adjusted diagnostic accuracy metrics decreased overall compared to the
missing and recovered data approaches, which was expected. The pooled sensitivity of the
nationally adjusted data approach was .652 (95% CI [.525, .761]). The FPR in the nationally
adjusted data approach was .021 [.0107, .04]). The pooled weighted DOR for the nationally
adjusted data approach fell to 96.63, and the Sp for the nationally adjusted data was .979.
CDC Adjusted Data
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The CDC adjusted diagnostic accuracy metrics decreased overall compared to all
previous data approaches. The pooled sensitivity of the CDC adjusted data approach was .384
(95% CI [.272, .51]). The FPR in the CDC adjusted data approach was .019 [.01, .038]). The
pooled weighted DOR for the CDC adjusted data approach fell to 33.29, and the Sp for the CDC
adjusted data was .98. Overall, recovering data increased Se and FPR, while epidemiologically
adjusting the data with yearly national prevalence and CDC prevalence decreased Se and
increased FPR (Figure 9).
Comparison of Data Approaches
In the bivariate analysis for the MADA, Se increased for the recovered data (mean Se =
.759, 95% CI [.646, 0.845]), then decreased for national prevalence adjustments and the CDC
prevalence adjusted data (Figure 9). The pooled FPR increased after recovering missing data and
applying epidemiological prevalence adjustments from a pooled FPR of .01 in the original data
with missing values to the largest FPRs in the recovered and nationally adjusted data (FPR =
.021) and slightly lower with the CDC adjusted data approach pooled FPR of .019 (see Table
10). Specificity decreased slightly with the application of each data approach but did not
decrease more than one percentage point from the original missing data approach Sp of .99.
Lastly, the DOR decreased after missing data recovery and epidemiological adjustments
compared to the original missing data (DOR = 336.55). The DOR values in the recovered data
approach (DOR = 163.38), nationally adjusted data (DOR = 96.63), and CDC adjusted data
(DOR = 33.29) decreased from the original study data DOR, consistent with the decrease in
sensitivity that results in a lower positive LL, which is the numerator for the diagnostic odds
ratio.
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Table 10
Cochran’s Q, Tau2 and I2
Approach

pSens, 95% CI

pFPR

pSpec

pDOR

Missing
Recovered
Nationally
Adjusted
CDC Adjusted

0.752 [.617, .851]
0.759 [.646, 0.845]

0.010 [.006, 0.017]
0.020 [.011, 0.040]

0.990
0.979

336.52
163.42

0.652 [.525, 0.761]

0.021 [.011-0.040]

0.979

96.67

0.384 [.272, 0.509]

0.010 [.019-0.010]

0.981

33.29

Figure 10
Barchart of multivariate calculation of Se and FPR

Exploratory Statistical Comparison of Data Approaches
Differences in Se, DOR, and FPR among the data approaches were examined first with a
non-parametric omnibus test using the Kruskal-Wallis test. Next, the Dunn test post-hoc multiple
comparison tests using the Dunn test were used to compare Se, DOR, and FPR in pairs across the
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four data approaches. The Dunn test was deemed the most appropriate post hoc test after running
the Kruskal-Wallis test due to the constraints of comparing data sources of different lengths. The
complete cases of the original data samples were smaller (n=20) than the other three data
approaches (n=28). Furthermore, the Dunn test is more likely to detect significant differences
than other post hoc tests since the Dunn test preserves the ranks used by the Kruskal Wallis test
(Dunn 1961). Second, the Dunn test is more appropriate when there are more than two groups to
compare and is less likely to be affected by outliers and lead to false positives than other tests
(Hsu, 1996). The significance level for all tests was set to .05. The χ2 test statistic, degrees of
freedom (df), and p-value for the Kruskal-Wallis test are reported in Table 11, and the results for
the post hoc tests are reported in Table 12.
The overall result of the Kruskal-Wallis test for differences in mean Se was significant
(χ2 = 22.915, p-value < .001), which provided evidence of meaningful differences in Se that
warranted further investigation with the post hoc tests. Similarly, the results comparing DOR
across the different data approach samples were significant (χ2 = 17.910, p-value < .001). The
Kruskal-Wallis Rank Sum test for FPR was not significant (χ2 = 4.057, p-value = .255).
All results of the Dunn test comparisons use the adjusted p-value to protect the false
discovery rate. All means are the means of Se, FPR, and DOR derived from the bivariate
analysis using the Reitsma function. The results of the Dunn test showed significant differences
in mean Se between the CDC adjusted data approach and each of the other data approaches
(Table 12). The difference in mean Se between the original data (M = .723) and the CDC
adjusted (M = .422) data approach (Z = 4.23, p < .001). The difference in mean Se between the
recovered data approach (M = .628) and the CDC adjusted (M = .422) data approach was
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significant (Z = 2.504, p = .025). All other pairwise comparisons for Se were not significant
(Table 12).
The Dunn test results for DOR yielded significant results for the difference in pooled
DOR between the original data (M = 1709.797) with missing values and the CDC prevalence
adjusted data (M = 120.096) approach (Z = 4.023, p < .001). The difference in pooled DOR in
the recovered data (M = 1277.462) and CDC prevalence adjusted data (M = 120.096) was also
significant (Z = -3.004, p = 0.008). All other comparisons for DOR were not significant (Table
11). The results for pairwise comparisons of pooled FPR among the four data approaches are
included in Table 11b but are not reported here since the Kruskal-Wallis test for overall
differences failed to reject the null hypothesis of no difference in pooled FPR among the four
data approaches (Table 11).

Table 11
Kruskal-Wallis Rank Sum Test Comparing Pooled Se, FPR, and DOR Across Data Approaches
Kruskal-Wallis χ2

df

p

Se by Approach

22.915

3

< .001

FPR by Approach

4.057

3

0.255

DOR by Approach

17.91

3

< .001
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Dunn Multiple Comparisons Tests
Measure

Comparison

Z

p (unadjusted

p (adjusted)

Se

Missing Data Original National Prevalence Adjusted

1.954

.051

.076

Missing Data Original - CDC
Prevalence Adjusted

4.239

< .001

< .001

2.504

.012

.025

0.674

.500

.500

-1.402

.161

.193

-3.906

< .001

< .001

Missing Data Original National Prevalence Adjusted

-1.675

.094

.282

Missing Data Original - CDC
Prevalence Adjusted

-1.805

.071

.427

National Prevalence Adjusted CDC Prevalence Adjusted

-0.142

.887

1.000

Missing Data Original –
Recovered Data

-1.631

.103

.206

National Prevalence Adjusted Recovered Data

0.049

.961

.961

Prevalence CDC Adjusted Recovered Data

0.191

.849

1.000

Missing Data Original National Prevalence Adjusted

2.006

.045

.067

Missing Data Original – CDC
Prevalence Adjusted

4.023

< .001

< .001

National Prevalence Adjusted Prevalence CDC Adjusted

2.209

.027

.054

National Prevalence Adjusted CDC Prevalence Adjusted
Missing Data Original Recovered Data
National Prevalence Adjusted Recovered Data
Prevalence CDC Adjusted Recovered Data
FPR

DOR
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Missing Data Original Recovered Data

1.280

.201

.241

National Prevalence Adjusted Recovered Data

-0.795

.426

.426

CDC Prevalence Adjusted Recovered Data

-3.004

.003

.008

4
4.1
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METAREGRESSION

Data Approaches with No Covariates

Original
The first step in the metaregression used the Reitsma function to summarize the pooled
Se, FPR, log-likelihood (LL), and area under the curve (AUC) for the data approaches. The
Reitsma model pooled Se for the recovered data approach was .752 (95% CI [.617, 0.852). The
pooled FPR was .009 (95% CI [0.006, .017), the LL was 68.811, and the AUC was .979
unnormalized.
Recovered Data
The next step in the metaregression comparisons used the recovered data approach,
where missing data values from the original studies were recovered. The Reitsma model pooled
Se for the recovered data approach was .759 (95% CI [.646, 0.845). The pooled FPR was .021
(95% CI [0.011, .040), the LL was 59.310, and the AUC was .934 unnormalized. All measures
of the recovered data approach performed better than the two population-adjusted measures, as
expected (Table 13).
Nationally Adjusted Data
The Reitsma model pooled Se for the nationally adjusted data approach was .652 (95%
CI [.525, 0.761]). The pooled FPR was .021 (95% CI [.011, 0.040]), the LL was 103.086, and the
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AUC was .936. The nationally adjusted data approach performed better than the CDC adjusted
measures. Yet, the AUC was slightly lower than the unnormalized AUC for the recovered data
model, where the original study data missing data was recovered and complete.
CDC Adjusted Data
The Reitsma model pooled Se for the CDC adjusted data approach was .384 (95% CI
[.272, .509]). The pooled FPR was .019 (95% CI [.010, 0.038]), the LL was 62.379, and the
AUC was .86. Overall, the general trend for the diagnostic accuracy metrics to take a sharper
penalty after adjusting to CDC reported prevalence continued.
Comparison of Data Approaches
In all three data approaches, the AUC was high and above 90% except for the CDC
adjusted approach (AUC = .86). The highest AUC was in the original data using complete cases
(AUC = .979), followed by the AUC in the recovered data approach (AUC = .955) and
nationally adjusted data approach (AUC = .934), followed lastly by the CDC approach (AUC =
.86). Sensitivity remained highest in the missing and recovered data approaches (Table 13) and
the epidemiological adjustments to simulate the expected TN and FN (missed cases) based on
reported prevalence continued to lower Se and increase the FPR. However, the FPR in the
recovered and nationally adjusted data was slightly higher than the FPR in the CDC adjusted
data and noticeably higher than the FPR in the original study samples with missing data.
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Table 13
Metaregression comparisons of Data Approaches
Se, 95% CI

FPR, 95% CI

LL

AUC

Missing

0.752 [.617, .852]

0.010 [.006, .017]

68.811

0.979

Recovered

0.759 [.646, .845]

0.021 [.011, .040]

64.599

0.955

Nationally Adjusted 0.652 [.525, .761]

0.021 [.011, .040]

59.310

0.934

CDC Adjusted

0.019 [.010, .038]

62.379

0.86

4.2

0.384 [.271, .509]

US vs. Other Nations

Original
The first metaregression test used nation as an independent variable category for
comparison predicting the measures of pooled sensitivity and FPR, and was performed for each
data approach (Table 14). The pooled Se was higher in the non-US nations (M = .80) than in the
US studies (M = .66) in the original data was higher in the yet the metaregression results were
not significant (Se β= -0.493, 95% CI [-1.874, 0.888], p = .484). The coefficient for FPR in the
recovered data source (fpr β = .216, 95% CI [-1.020, 1.452], p = .732) was not significant for the
difference in FPR for the US-based studies (M = .02) versus the non-US based studies (mean
FPR = .01).
Recovered Data
The results were not significant for pooled sensitivity (Se β= -.683, 95% CI [-1.853,
0.487], p = .253) and indicated no significant difference in sensitivity between the US based
studies (M = .63) and the non-US based studies (M = .77) in the recovered data approach (Table
13). The coefficient for FPR in the recovered data source (fpr β = .235, 95% CI [-1.276, 1.746], p
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= .760) was also non-significant for the comparison between US studies (M = .07) and non-US
studies (M = .07).
Nationally Adjusted Data
The nationally adjusted data approach source results showed no significant differences in
sensitivities between the US based studies (M = .60) and the non-US based (M = .64) studies (Se
β = -.265, 95% CI [ -1.435, 0.904], p = .656). The coefficient for FPR also non-significant (fpr β
= .234, p = .038, 95% CI [-1.279, 1.746]) for the comparison between US studies (M = .07) and
non-US studies (M = .07).
CDC Adjusted Data
The CDC adjusted data approach source results showed that the sensitivities were not
significantly different for US based studies (M = .47) versus the non-US (M = .40) based studies
(Se β = -.473, 95% CI [ -0.658, 1.603], p = .473). The coefficient for FPR in the CDC adjusted
data source was not significant (fpr β = .304, 95% CI [-1.213, 1.821], p = .694) for the subgroup
comparison of US based studies (M = .07) versus non-US based studies (M = .09).
Comparison of Data Approaches
Overall, the effect of the dichotomized variable ‘Nation’ was not a significant modifier of
Se or FPR in any of the data approaches. The pooled Se across the metaregressions of the
missing data original, recovered, and nationally adjusted data approaches were higher in the nonUS based studies (n = 14, 20 for missing vs. other approaches) than in the US-based studies (n =
6, 8 respectively for missing vs. other approaches) though the results were not significant. Pooled
FPR in the originals with missing data, recovered, and nationally adjusted data approaches were
slightly lower in the non-US studies than in the US studies. The direction of the differences in Se
and FPR reversed in the CDC adjusted metaregression with US studies showing a trend towards
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higher Se and lower FPR vs. the non-US studies (Figure 14), yet the coefficient results were not
significant.

Table 14
Metaregression on US vs. Other Nations for all Data Approaches
95% CI
Approach

Effect

Estimate

SE

Z

LL

UL

p

Missing

Se (Intercept)

1.289

0.411

3.134

0.483

2.096

.002

Se Nation - US

-0.493

0.704

-0.700

-1.874

0.888

.484

FPR (Intercept)

-4.679

0.347

-13.494

-5.358

-3.999

<.000

FPR Nation - US

0.216

0.631

0.343

-1.020

1.452

.732

Se (Intercept)

1.374

0.343

4.004

0.702

2.047

.000

Se Nation - US

-0.683

0.597

-1.144

-1.853

0.487

.253

FPR (Intercept)

-3.921

0.417

-9.408

-4.738

-3.104

<.0001

FPR Nation - US

0.235

0.771

0.305

-1.276

1.746

.760

Se (Intercept)

0.718

0.332

2.161

0.067

1.369

.031

Se Nation - US

-0.265

0.597

-0.445

-1.435

0.904

.656

FPR (Intercept)

-3.918

0.417

-9.395

-4.736

-3.101

<.0001

FPR Nation - US

0.234

0.772

0.303

-1.279

1.746

.762

Se (Intercept)

-0.614

0.313

-1.958

-1.228

0.001

.050

Se Nation - US

0.473

0.577

0.820

-0.658

1.603

.412

FPR (Intercept)

-4.008

0.422

-9.500

-4.835

-3.181

<.0001

FPR Nation - US

0.304

0.774

0.393

-1.213

1.821

.694

Log Likelihood

AIC

BIC

Recovered

Nationally
Adjusted

CDC
Adjusted

Missing

68.811

-123.622

-115.177

Recovered

64.599

-119.198

-109.072

Nationally
Adjusted

59.310

-108.621

-98.494

CDC
Adjusted

62.379

-114.757

-104.630
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Figure 11
SROC plots of US studies and Non-US using Recovered, Nationally, and CDC Adjusted Data

5

DISCUSSION

Autism screening has experienced numerous setbacks in recent years as purportedly highquality population screening tools, like the M-CHAT, have been found to have lower accuracy
than expected when methodologically rigorous longitudinal studies are conducted (e.g., Guthrie
et al., 2019). Two major issues unaddressed methodologically in the systematic review literature
that informs screening policy decision center on missingness. The weightier issue is that studies
rarely follow up on false negatives leaving sensitivity estimates of (typically) cross-sectional
studies potentially inflated and providing an over-optimistic view of marketed screening tools.
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As such, there is a need for methods to determine whether screening tools may be providing
overly optimistic diagnostic accuracy assessments. Additionally, screening studies frequently
only partially report data from the confusion matrices used as the raw data to develop diagnostic
accuracy metrics. This is a relatively minor issue addressed here via back-calculating confusion
matrix data based on data available in the study.
28 study samples were selected for the final analysis. The final 28 studies selected were
used to conduct a univariate and bivariate meta-analysis of diagnostic accuracy (MADA) with
four approaches to the data, including complete cases of the original data, recovered data,
national prevalence adjusted data, and CDC adjusted data. To address these diagnostic accuracy
measures across different methods of adjusting the original study data, including recovering
missing data (Recovered data approach), using national yearly prevalence (nationally adjusted
approach) and CDC yearly prevalence measures from the ADDM in the US to epidemiologically
adjust the study measures for potentially missed cases (CDC adjusted data approach).
Our analyses included a univariate test of heterogeneity in sensitivity and specificity and
a bivariate method for Cochran’s Q test on heterogeneity in DOR. The univariate results showed
a definitive trend where each data adjustment, including recovering missing data and then
epidemiologically adjusting the recovered data, increased the detection of heterogeneity of
sensitivity and specificity across studies. The stepwise increase in test statistics for the univariate
tests for heterogeneity of sensitivities and specificities (Table 7) and the Cochran Q test of DOR
heterogeneity (Appendix D) using the Mantel Haenszel method (Mathes & Kuss, 2018). The
Cochran Q test of heterogeneity using the DSL method in this study was not significant. Yet, the
mada package function application of the DSL method was overly conservative, prone to a high
type one error rate (Röver et al., 2015), and is known to have lower power for detecting
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significant differences (Mathes & Kuss, 2018). A post-hoc test ran in the R package metaphor
using the HKSJ correction revealed significant heterogeneity in outcomes for all data approaches
(Appendix D). The univariate and bivariate heterogeneity test results showing increases in both
χ2 and Cochran’s Q test statistics suggest that recovering missing data, then additionally
adjusting for population estimates may reveal more detectable heterogeneity within a collection
of studies than is often reported with data that has not been recovered and adjusted to address
study results where follow-up data is not available.
The next stage of the analysis compared Se, Sp, FPR, and DOR in a univariate and
bivariate analysis. Differences in bivariate calculated sensitivity, FPR, and DOR were tested
using the Wilcoxon Rank Sum test and followed up with the Dunn multiple comparisons test
before carrying out metaregressions with and without the covariate for nation of origin. The
recovered data, the national prevalence, and the CDC adjusted data systematically in the
univariate analyses increased the test statistics for heterogeneity and showed a systematic
decrease in Sp and DOR, a systematic increase in the FPR, and a systematic decrease in Se after
missing study values were recovered, and the data was epidemiologically adjusted.
Notably, Sensitivity systematically decreased for each epidemiological prevalence
adjustment (national and CDC) in both the univariate and bivariate analyses. The mean
univariate Se was highest in the recovered data approach (0.732, 95% CI [.513, .844]) and
slightly lower for the original missing data approach (.723, 95% CI [.493, .847]). The mean
univariate Se decreased when the recovered data was adjusted for national yearly prevalence
(0.628, 95% CI [.44, 0.765]) and decreased more after the CDC yearly prevalence adjustment
(0.422, 95% CI [.293, .554]). The pooled Se derived from the Reitsma function slightly increased
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Se for each approach (0.752, .759, .652 for missing, recovered, and national), then decreased
much more in the CDC adjusted approach (pooled Se = .384).
Sensitivity remained highest in the missing and recovered data approaches (Table 13),
and the epidemiological adjustments to simulate the expected TN and FN (missed cases) based
on reported prevalence lowered Se and increased the FPR over the original data source FPR. The
subgroup comparisons using the dichotomy of US vs. non-US showed that FPR was slightly
higher in US studies in the original data with missing values and the CDC adjusted approach,
though those results were not significant. There was no difference in FPR between the recovered
data approach and the national prevalence data approach (M = .07). Overall, the pooled FPR in
the recovered and nationally adjusted data were not meaningfully different. Yet, the FPR
increased over the original study data after applying each data adjustment. The effect of the
adjustment on specificity was more severe after the national prevalence and CDC reported
prevalence approach adjustments. The DOR followed the reduction pattern in Sp, where
recovering missing data led to a slight decrease, then epidemiological adjustments led to more
severe decreases (see Table 8 and Table 10). Recovering missing data and adjusting for
epidemiological prevalence provided a more real-world accurate picture of the diagnostic
accuracy of the ASD screening tools reviewed in our sample.
Øien et al. (2019) argued that the lack of diagnostic accuracy metrics for screen negatives
and lack of follow-ups for falsely missed children results in an incomplete picture of autism
screening tool accuracy. Additionally, unaccounted for heterogeneity in autism screening studies,
the low inclusion of real-world population-based studies, and the lack of multiple screenings and
follow-up likely results in biased diagnostic accuracy measures, usually reflected in a biased
sensitivity that is higher than is reported in a true population sample (Øien et al., 2019). Our

META-ANALYSIS OF DIAGNOSTIC ACCURACY OF ASD SCREENING TOOLS

70

results are consistent with Øien’s contention (2019) and showed a systematic decrease in both Se
and Sp and an increase in the FPR after missing data was recovered and used, and diagnostic
accuracy measures were epidemiologically adjusted using national and yearly reports of ASD
prevalence. The results regarding a decrease in Se were also consistent with prior studies using
epidemiological prevalence data to simulate a more accurate TN and missed case FN (Barbaro &
Dissanayake, 2010; Guthrie et al., 2020). The current results suggest that using population
adjustments might aid the field in identifying screening tools that are weaker than those
promoted by cross-sectional studies.
The meta-regression comparing the US and non-US studies did not reveal significant
differences in FPR. The result for the difference in FPR in the missing data approach was not
significant, yet all three data approaches showed that FPR was slightly higher in the US studies
than in the non-US studies (Table 14). This result suggests that children screened in the US
studies were more likely to falsely screen positive. The epidemiological prevalence adjustments
decreased the TN in many studies and led to a smaller denominator for the FPR, thus increasing
the FPR though this effect was attenuated somewhat in the bivariate analysis resulting in a larger
increase in the revered and nationally adjusted data approaches. The FPR also increased when
missing data was recovered. The data selection process and only reporting certain measures may
introduce another source of heterogeneity and bias in MADAs for ASD (Oien et al., 2018).
Furthermore, the increase in FN and the FPR suggests a larger number of children potentially
missed in the study screening who have autism and require identification for services (Guthrie et
al., 2020). In the example of this umbrella review and meta-analysis, the FPR indicated an
increase of children potentially falsely identified or diagnosed as an ASD case as compared to
other nations.
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Overall, recovering the missing data allowed data to be more fully tested and vetted,
which is a first step in more accurate reporting of diagnostic accuracy measures. Thus, at a
minimum, meta-analyses of autism screening should seek to recover as much lost data as
possible. The national prevalence results overall were the more appropriate prevalence
adjustment for this study's samples, given that around 60% of the studies were of non-US origin.
The CDC reports of prevalence were higher than those reported for other nations, where
systematic cultural differences may affect how and when autism is suspected, tested, and
identified (Chiarotti and Venerosi, 2020). In general, the CDC adjustments may have overpenalized the diagnostic accuracy measures, particularly the measures from non-US countries
and countries where reported autism prevalence is less than what has been reported by the CDC
(Maenner et al., 2018).
While this study initially focused on the effects of missing data recovery and
epidemiological adjustments, the decision was made to stratify by US and non-US studies to
display the utility of considering differences in diagnostic accuracy after recovering missing data
and performing epidemiological adjustments on the study sample data. Adjusting the data,
including the first step of recovering missing data, then applying epidemiological adjustments
revealed an increase in potentially misclassified screenings through unilateral increases in FN for
all studies adjusted for national and CDC prevalence, decreases in TN, and the subsequent
increase in FPR.
Our data suggest that a focus on decreasing FP to increase specificity is warranted for the
early identification of children with ASD (Robins et al., 2014). However, epidemiologically
adjusting the data using reported ASD prevalence will likely decrease the reported sensitivity for
many studies, given that the adjustments will increase the number of FNs representing missing
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ASD cases (Barbaro & Dissanayake, 2010; Guthrie et al., 2020). The results of the
metaregression for Se and FPR by whether the study was a US study or a non-US study revealed
a higher FPR in US based studies than non-US studies in all data approaches except for the CDC
adjustments. The issue of FPR among US studies could warrant further investigation.
Ultimately this study provides additional evidence that many screenings are potentially
misclassified as either TN, and that future screening validation studies should include provisions
for follow-up or epidemiological adjustments when follow-up is not available. Since ASD is a
low prevalence condition, the initial screening produces diagnostic results with high sensitivity
and specificity but a low positive predictive value (PPV) and negative predictive value (NPV).
Therefore, to increase the population predictive values, it is important to conduct secondary
screening using the results of the initial screenings. Secondary screenings have the advantage of
providing a sample pool with a higher prevalence of ASD, which helps raise the PPV and NPV
of diagnostic tests. When missing data was recovered in this study and the data were adjusted
using the national prevalence approach, PPV increased, and Se decreased, suggesting that the
originally reported Se may be biased higher. The ratio of total screen positives to the full sample
may be lower than the epidemiologically reported prevalence suggests. The NPV decreased only
slightly after the data approach adjustments and no more than two percentage points after the
adjustment for national prevalence, and the decrease in Sp was minimal, suggesting the data
adjustments had a minimal impact on the screening tool’s ability to screen non-cases.
Our results resonate with recent research from Guthrie et al. (2019), who indicated that
current literature on autism screening studies identified too few cases in the past after accounting
for known prevalence. Furthermore, long-term follow-up updates to measures showed that the
observed M-CHAT diagnostic accuracy was lower than initially reported in the literature

META-ANALYSIS OF DIAGNOSTIC ACCURACY OF ASD SCREENING TOOLS

73

(Barbaro & Dissanayake, 2010). Guthrie et al. (2020) reported sensitivity was .388 and a
specificity of .949, which were notably lower than the sensitivity of .911 and specificity of .955
reported by Robins et al. (2014). Our study provided preliminary evidence that recovering
missing data and offering adjustments for recorded national prevalence (Barbaro & Dissanayake,
2010; Guthrie et al., 2020) could help researchers obtain more real-world estimates of diagnostic
accuracy that align with public health data on autism prevalence.
This study highlighted areas concerning diagnostic accuracy that can improve how crosssectional screening research is conducted and reported, which will inform the best practices for
better early identification of autism. This study showed that recovering missing data can increase
the analysis's robustness and accuracy, giving a more reliable picture of the diagnostic accuracy
measures reported in the original studies. This study also shows that adjusting the confusion
matrix measures according to epidemiological data on autism prevalence results in diagnostic
accuracy that better reflects the real-world accuracy of the screeners when used in the field at the
population level. Planning for follow-ups with the screened population can provide more
accurate reports on false negatives and false positives.
6

LIMITATIONS

This study encountered several limitations while selecting studies for the umbrella review
and meta-analysis and conducting the final analysis. The intent of selecting studies from different
analyses was to gather a wide variety of studies using different ASD screening tools. However,
data extraction efforts showed a significant overlap of original study sources between the
selected meta-analyses. The selection process resulted in a smaller pool of studies (n = 28) than
would have proven ideal for an umbrella review and meta-analysis of population-level studies. A
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larger initial pool of studies would have increased the power for all tests and allowed for more
options for subgroup comparisons.
The second limitation was the uneven distribution of screening tools used in the studies,
where 19 of the final 28 studies (67.86%) were different versions of M-CHAT studies. The same
issue also arose for the nation of origin, where the US studies represented the single largest
group which then required collapsing all the other nations into a non-US group for comparisons
in metaregression. Group balancing given larger samples would have reduced selection bias and
allowed additional comparisons to address differences in diagnostic accuracy measures across
different geographic regions.
The third minor limitation arose when screening out studies. When studies were screened
out for reporting a case prevalence of greater than 10%, reducing the studies sampled to a
smaller prevalence range reduced the amount of heterogeneity reported in studies of a similar
design (Sanchez-Garcia et al., 2019). As a result, our bivariate test of heterogeneity using the
DerSimonian–Laird method resulted in almost no heterogeneity. In contrast, Sanchez-Garcia et
al. (2019) included study samples with a case prevalence as high as 27% in one study and
reported a large amount of heterogeneity.
The last major limitation was methodological. We aimed to compare the effect of various
adjustments to original study data on diagnostic accuracy measures. Yet, the r package ‘mada’
we selected for the analysis does not permit missing values. Our workaround was to calculate Se,
Sp, PPV, NPV, and FPR manually for the univariate analysis and then select only ‘complete
cases’ where no data was missing for TP, FP, TN, or FN and use that filtered data for
comparison, which resulted in a smaller sample (n = 28). Choosing methods that allow for the
omission of NA values or only comparing adjusted data to the pooled metrics reported in the
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original studies would allow for a better comparison between what is reported in the literature
and what results after recovering missing data and applying epidemiological adjustments based
on regional and yearly prevalence. Despite the limitations above, this study shows that
recovering missing data can result in more accurate diagnostic accuracy measurements. More
importantly, recovering missing data is required for simulating real world TNs and FNs with
epidemiological adjustments where a lack of follow-up in screening studies precludes correction
for misclassified screenings.
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Appendix B. Matrix of Studies and Author Overlap
Original Study

Sanchez-

Levy et

Olmstead

Petrocchi et

Desideri

Salgado-

Garcia et

al. (2020)

(2019)

al. (2020)

(2021)

Cacho et al.

al. (2019)
Baduel et al. (2016)

(2021)
X

Baranek (2015)

X

Barbaro & Dissanayake

X

X

X

(2010)
Baron-Cohen (1996)

X

Brooks (2015)
Canal-Bedia (2011)

X

Chlebowski et al. (2013)

X

X

X
X

Dietz et al. (2006)

X
X

Cuesta-Gomez (2016)
Dereu et al. (2010)

X

X
X

X

Eaves et al. (2006)

-

X

X

Fäldt et al. (2021)
Gong et al. (2018)

X

Hedley et al. (2010)

X

Hoang et al. (2019)
Honda et al. (2005)

X
X

Honda et al. (2009)

X

Inada et al. (2011)

X

Kamio et al. (2014)

X

X

X
X

X

Kanne et al. (2018)

X

Kaur et al. (2018)

X

Kerub et al. (2018)

X
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Kleinman et al. (2007)

X

Kondolot et al. (2016)

X

Magan-Maganto et al. (2018)

X

Matson et al. (2018)

X

Miller et al. (2011)

X

X

Moore et al. (2018)
Nygren et al. (2012)

93

X
X

X

X

Oller et al. (2010)
Oner & Munir (2019)

X

X

Pierce et al. (2011)
Pierce et al. (2016)
Robins et al. (2014)

X
X

X

X

Scarpa et al. (2012)

X

Seif-Eldin et al. (2008)

X

Snow & Lecavalier (2008)
Srinivasan et al. (2016)

X

Srisinghasongkram et al.

X

(2016)
Sturner et al. (2016)

X

Sun et al. (2015)
Toh et al. (2018)

X

Toizumi et al. (2017)

X

Topcu et al. (2018)

X

Tsai et al. (2019)

X

Turner-Brown (2012)

X

VanDenHeuvel et al. (2007)
Wetherby et al. (2014)
Wiggins et al. (2014)

X

META-ANALYSIS OF DIAGNOSTIC ACCURACY OF ASD SCREENING TOOLS
Wiggins et al. (2014)

X

Wong et al. (2018)

X

Zahorodny et al. (2018)

X

Appendix C. Wilcoxon Rank Sums Comparisons Test
Measure

Approach

W

p

95% CI

Se

Missing Data Original - National
Prevalence Adjusted*
Missing Data Original Prevalence CDC Adjusted*
National Prevalence Adjusted Prevalence CDC Adjusted*
Missing Data Original Recovered Data
National Prevalence Adjusted Recovered Data
Prevalence CDC Adjusted Recovered Data
Missing Data Original - National
Prevalence Adjusted*
Missing Data Original Prevalence CDC Adjusted*
National Prevalence Adjusted Prevalence CDC Adjusted*
Missing Data Original Recovered Data
National Prevalence Adjusted Recovered Data
Prevalence CDC Adjusted Recovered Data
Missing Data Original - National
Prevalence Adjusted*
Missing Data Original Prevalence CDC Adjusted*
National Prevalence Adjusted Prevalence CDC Adjusted*
Missing Data Original Recovered Data
National Prevalence Adjusted Recovered Data
Prevalence CDC Adjusted Recovered Data

322

0.385

-0.104, 0.161

380.5

0.036

0.004, 0.315

464

0.0001

0.19, 0.519

45

0.009

0.187, 0.479

190

0.0001

0.339, 0.576

189

0.0001

0.208, 0.391

335

0.254

-94.996, 570.825

382.5

0.033

3.152, 725.843

470

7.39E-05

97.867, 960.698

45

0.009

243.0852, 1654.229

190

0.0001

339.914, 1893.983

189

0.0002

97.391, 1157.772

199

0.093

-0.027, 0.0012

199

0.093

-0.027, 0.0012

199

0.093

-0.027, 0.001

0

0.0092

-0.0013, 0

0

0.0001

-0.0003, -0.0001

14

0.001

-0.0002, 0

DOR

FPR
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Appendix D. Bivariate Heterogeneity Test, HKSJ correction
Bivariate Test of Heterogeneity in Study Outcomes (DOR) using the Hartung-Knapp-SidikJonkman (HKSJ) correction
95% CI
Approach

est Q

lower

upper

p

df

Missing

356.630

137.869

922.49

<.0001

19

Recovered

167.503

66.549

421.585

<.0001

27

Nationally Adjusted

100.927

40.954

248.735

<.0001

27

CDC Adjusted

31.627

15.823

63.213

<.0001

27
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